Page last updated: 2024-11-07

prednisone and Anemia

prednisone has been researched along with Anemia in 253 studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.

Research Excerpts

ExcerptRelevanceReference
"To test the hypothesis that combination treatment with lenalidomide and prednisone will yield a higher erythroid response rate in patients with non-del(5q) lower-risk myelodysplastic syndromes compared to the historical clinical trial data with lenalidomide monotherapy, which reported a 26% transfusion independence rate."9.30Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. ( Al Ali, NH; Cogle, C; Komrokji, RS; Lancet, JE; Lis, AF; Padron, E; Sallman, D; Tinsley, S, 2019)
"The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)."9.24Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. ( Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS, 2017)
"We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin < 10 g/dL)."9.19Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. ( Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Newberry, K; Pemmaraju, N; Pierce, S; Shastri, A; Verstovsek, S; Zhou, L, 2014)
"We conducted a prospective study to compare epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab (R-miniCEOP) with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOP) for the treatment of "fit" elderly patients with diffuse large B-cell lymphoma (DLBCL)."9.16Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINT ( Alvarez, I; Arcari, A; Baldini, L; Chiappella, A; Di Rocco, A; Federico, M; Fragasso, A; Gobbi, PG; Ilariucci, F; Liberati, AM; Luminari, S; Mammi, C; Marcheselli, L; Mazza, P; Merli, F; Musso, M; Rossi, G; Salvi, F; Stelitano, C; Tucci, A, 2012)
"5 or 2 mg/d with or without an abbreviated course of prednisone is well tolerated in patients with myelofibrosis and active in the treatment of anemia."9.14Pomalidomide is active in the treatment of anemia associated with myelofibrosis. ( Barosi, G; Bekele, BN; Cervantes, F; Deeg, HJ; Gale, RP; Gisslinger, H; Kantarjian, HM; Kvasnicka, HM; Mesa, RA; Paquette, RL; Passamonti, F; Rivera, CE; Roboz, GJ; Tefferi, A; Thiele, J; Vardiman, JW; Verstovsek, S; Zhang, Y, 2009)
"This study has retrospectively analyzed the efficacy of single-agent prednisone, usually given after failure of other therapies, in 30 patients with myelofibrosis (MF) and severe anemia."7.83Long-term results of prednisone treatment for the anemia of myelofibrosis. ( Alvarez-Larrán, A; Barba, P; Cervantes, F; Correa, JG; Ferrer-Marín, F; García-Gutiérrez, V; Gómez, M; Hernández-Boluda, JC; Herrera, JC; Kerguelen, A; Martínez-Trillos, A; Xicoy, B, 2016)
"To observe the clinical effects of low-dose thalidomide (THAL) and prednisone (PRED) with or without danazol (DANA) in patients with primary myelofibrosis (PMF) associated anemia."7.80[Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia]. ( Fang, L; Hu, N; Li, B; Pan, L; Qin, T; Qu, S; Xiao, Z; Xu, J; Xu, Z; Zhang, H; Zhang, Y, 2014)
"A total of 18 patients with newly diagnosed/untreated MM and renal insufficiency (GFR < 35 ml/min) were treated with bendamustine, prednisone, and bortezomib (BPV)."7.78Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. ( Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T, 2012)
" An apparent link is described between the use of MMF with prednisone to treat pemphigus vulgaris and the development of red blood cell anemia."7.74Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone. ( Scheinfeld, N, 2007)
"A 4-year-old, spayed female toy fox terrier developed multiple epidermal hamartomas and squamous cell carcinomas in situ following chronic immunosuppressive therapy with prednisone and cyclosporine for management of an immune-mediated nonregenerative anaemia."7.73Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine. ( Callan, MB; Mauldin, E; Preziosi, D, 2005)
"Our study suggests that low-dose oral pulse methotrexate constitutes an effective therapeutic alternative in elderly patients with generalized bullous pemphigoid."7.70Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. ( Albertioni, F; Heilborn, JD; Peterson, C; Ståhle-Bäckdahl, M; Stephansson, E; Vassilaki, I, 1999)
"To test the hypothesis that combination treatment with lenalidomide and prednisone will yield a higher erythroid response rate in patients with non-del(5q) lower-risk myelodysplastic syndromes compared to the historical clinical trial data with lenalidomide monotherapy, which reported a 26% transfusion independence rate."5.30Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. ( Al Ali, NH; Cogle, C; Komrokji, RS; Lancet, JE; Lis, AF; Padron, E; Sallman, D; Tinsley, S, 2019)
"The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)."5.24Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. ( Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS, 2017)
"Data were obtained from a Phase II, randomized, double-blind Bayesian pick-the-winner trial of prednisone and pomalidomide in patients with MPN-associated myelofibrosis and anemia (red blood cell-transfusion dependence)."5.19Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. ( Cervantes, F; Gale, RP; Hudgens, S; Khan, ZM; Mesa, R; Passamonti, F; Rivera, C; Tefferi, A; Tencer, T; Verstovsek, S, 2014)
"We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin < 10 g/dL)."5.19Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. ( Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Newberry, K; Pemmaraju, N; Pierce, S; Shastri, A; Verstovsek, S; Zhou, L, 2014)
"We conducted a prospective study to compare epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab (R-miniCEOP) with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOP) for the treatment of "fit" elderly patients with diffuse large B-cell lymphoma (DLBCL)."5.16Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINT ( Alvarez, I; Arcari, A; Baldini, L; Chiappella, A; Di Rocco, A; Federico, M; Fragasso, A; Gobbi, PG; Ilariucci, F; Liberati, AM; Luminari, S; Mammi, C; Marcheselli, L; Mazza, P; Merli, F; Musso, M; Rossi, G; Salvi, F; Stelitano, C; Tucci, A, 2012)
"5 or 2 mg/d with or without an abbreviated course of prednisone is well tolerated in patients with myelofibrosis and active in the treatment of anemia."5.14Pomalidomide is active in the treatment of anemia associated with myelofibrosis. ( Barosi, G; Bekele, BN; Cervantes, F; Deeg, HJ; Gale, RP; Gisslinger, H; Kantarjian, HM; Kvasnicka, HM; Mesa, RA; Paquette, RL; Passamonti, F; Rivera, CE; Roboz, GJ; Tefferi, A; Thiele, J; Vardiman, JW; Verstovsek, S; Zhang, Y, 2009)
"Epoetin alfa administered at 40,000 U weekly parallel to BEACOPP chemotherapy was safe in patients with advanced-stage HL and reduced the number of RBC transfusions but had no impact on fatigue and other PRO domains."5.14Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. ( Borchmann, P; Diehl, V; Engert, A; Flechtner, HH; Fuchs, M; Haverkamp, H; Josting, A; Lohri, A; Nogova, L; Rank, A; Sökler, M; Sturm, I; Topp, MS; Villalobos, M; Vogelhuber, M; Zenz, T; Zijlstra, J, 2010)
"Ninety-six patients with advanced chronic lymphocytic leukemia (CLL) (Stage C; anemia and/or thrombocytopenia of nonimmune origin) were randomized to receive either chlorambucil (CLR) (0."5.05Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. ( Alcalá, A; Bueno, J; Domingo, A; Ferrán, C; García-Conde, J; Giralt, M; Montserrat, E; Parody, R; Rubio, D; Sanz, MA, 1985)
"The effect of certain disease parameters on remission and survial time was evaluated in 482 patients with multiple myeloma treated with intermittent courses of melphalan-prednisone combinations."5.04Prognostic factors in multiple myeloma. ( Alexanian, R; Balcerzak, S; Bonnet, JD; Gehan, EA; Haut, A; Hewlett, JS; Monto, RW, 1975)
"This study has retrospectively analyzed the efficacy of single-agent prednisone, usually given after failure of other therapies, in 30 patients with myelofibrosis (MF) and severe anemia."3.83Long-term results of prednisone treatment for the anemia of myelofibrosis. ( Alvarez-Larrán, A; Barba, P; Cervantes, F; Correa, JG; Ferrer-Marín, F; García-Gutiérrez, V; Gómez, M; Hernández-Boluda, JC; Herrera, JC; Kerguelen, A; Martínez-Trillos, A; Xicoy, B, 2016)
"To observe the clinical effects of low-dose thalidomide (THAL) and prednisone (PRED) with or without danazol (DANA) in patients with primary myelofibrosis (PMF) associated anemia."3.80[Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia]. ( Fang, L; Hu, N; Li, B; Pan, L; Qin, T; Qu, S; Xiao, Z; Xu, J; Xu, Z; Zhang, H; Zhang, Y, 2014)
"A total of 18 patients with newly diagnosed/untreated MM and renal insufficiency (GFR < 35 ml/min) were treated with bendamustine, prednisone, and bortezomib (BPV)."3.78Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. ( Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T, 2012)
" An apparent link is described between the use of MMF with prednisone to treat pemphigus vulgaris and the development of red blood cell anemia."3.74Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone. ( Scheinfeld, N, 2007)
"A 4-year-old, spayed female toy fox terrier developed multiple epidermal hamartomas and squamous cell carcinomas in situ following chronic immunosuppressive therapy with prednisone and cyclosporine for management of an immune-mediated nonregenerative anaemia."3.73Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine. ( Callan, MB; Mauldin, E; Preziosi, D, 2005)
"Changes in hemoglobin (HGB) and serum albumin (SA) concentration associated with the onset of symptomatic erythema nodosum leprosum (ENL) were studied by comparing the values obtained on the day thalidomide or prednisone therapy commenced, with each patients' preceding values."3.71Decreases in mean hemoglobin and serum albumin values in erythema nodosum leprosum and lepromatous leprosy. ( Rea, TH, 2001)
" While a corticosteroid treatment with prednisone (1 mg/kg/d) did not show any efficacy upon anemia, the patient's pregnancy was followed by prolonged correction of hemoglobin, making possible the tapering of prednisone down to 10 mg/d."3.70[A case of post-partum remission of acquired dyserythropoiesis, a rare cause of anemia in disseminated lupus erythematosus]. ( Debandt, M; Hayem, G; Kahn, MF; Kettaneh, A; Lebail-Darné, JL; Meyer, O; Palazzo, E; Roux, S, 1998)
"Our study suggests that low-dose oral pulse methotrexate constitutes an effective therapeutic alternative in elderly patients with generalized bullous pemphigoid."3.70Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. ( Albertioni, F; Heilborn, JD; Peterson, C; Ståhle-Bäckdahl, M; Stephansson, E; Vassilaki, I, 1999)
"Of the 57 patients in this phase I trial, 55 participated in 1 of 2 dosing schedules that included rituximab (375 mg/m(2)) and cyclophosphamide (750 or 1,000 mg/m(2)) administered on day 1 of each 21-day cycle and prednisone (100 mg orally) days 2 to 6."2.76Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. ( Dumitrescu, O; Gerecitano, J; Hamlin, P; Horanlli, E; Iasonos, A; Mo, Q; Moskowitz, CH; Noy, A; O'Connor, OA; Pappanicholaou, J; Portlock, C; Rojas, CN; Sarasohn, D; Schulman, P; Straus, D; Zelenetz, AD; Zhang, Z, 2011)
"Lenalidomide therapy was continued indefinitely in patients exhibiting clinical benefit."2.74Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. ( Bueso-Ramos, C; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Manshouri, T; Quintás-Cardama, A; Ravandi, F; Thomas, D; Verstovsek, S, 2009)
"Prednisone was common to all three schedules and was given daily in an initial dosage of 0."2.64Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. ( Glidewell, O; Rai, KR; Sawitsky, A; Silver, RT, 1977)
"Waldenström macroglobulinemia is defined by the presence of monoclonal immunoglobulin IgM type (M-IgM) and evidence of lymphoplasmacytic bone marrow infiltration."2.53[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. ( Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S, 2016)
"Postpartum-acquired haemophilia A is a rare but potentially severe complication of pregnancy."2.45Postpartum-acquired haemophilia A: a description of three cases and literature review. ( Prejanò, S; Santoro, RC, 2009)
"Fever, arthritis and skin rash was constant."2.41[Adult Still's disease: study of a series of 11 cases]. ( Ben Maïz, H; Ben Taarit, C; Turki, S, 2002)
"Immune thrombocytopenic purpura is rarely reported in association with inflammatory bowel disease."2.40Inflammatory bowel disease and immune thrombocytopenic purpura: is there a correlation? ( Ammirati, M; Gruenstein, S; Kim, P; Korelitz, BI; Lipsey, L; Schwarz, S; Wisch, N; Zlatanic, J, 1997)
"Proximal renal tubular acidosis (RTA) complicated with anemiawas confirmed after admission."1.56[The 475th case: renal tubular acidosis, renal failure, anemia, and lactic acidosis]. ( Chen, G; Li, MX; Wu, D, 2020)
"DiGeorge syndrome is the most common chromosome microdeletion disease."1.43[Autoimmune disorder secondary to DiGeorge syndrome: a long-term follow-up case report and literature review]. ( Guo, JQ; Hua, Y; Lu, XT; Sun, Q; Xie, Y; Zhao, WH, 2016)
"Alveolar hemorrhage is a potentially life-threatening condition which is usually managed by the pulmonologist."1.43Severe Alveolar Hemorrhage - What's in it for the Gastroenterologist? ( Balaban, DV; Jinga, M; Jurcuţ, C; Laurila, K; Popp, A; Șotcan, M, 2016)
"Stevens-Johnson syndrome and toxic epidermal necrolysis are life-threatening dermatological conditions."1.42[Systemic lupus erythematosus presenting as Stevens-Johnson syndrome]. ( Bellakhal, S; Ben Kaab, B; Derbel, F; Douggui, MH; Souissi, A; Teyeb, Z, 2015)
"Cabazitaxel/prednisone has been shown to prolong survival versus mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or after docetaxel."1.40Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. ( Bracarda, S; Climent, MA; Fossa, S; Heidenreich, A; Hitier, S; Mason, M; Ozen, H; Papandreou, C; Sengelov, L; Van Oort, I, 2014)
"Cbz at a dosage of 25mg/m(2) intravenously every 3 wk combined with 5mg of oral prednisone twice a day."1.39Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. ( Albers, P; Arsov, C; Bokemeyer, C; Ecstein-Fraisse, E; Gschwend, J; Heidenreich, A; Heinrich, E; Honecker, F; Keck, B; Miller, K; Müller, SC; Otremba, B; Pfister, D; Retz, M; Rogenhofer, S; Scholz, HJ; Steiner, U; Trojan, L; Volkmer, B; Wirth, M, 2013)
"Two patients were presenting non-Hodgkin lymphoma, one had Hodgkin's disease, one had chronic myeloid leukaemia in progression and one had an undifferentiated lymphomatous process."1.38[Acquired ichthyosis and haematological malignancies: five cases]. ( Baybay, H; Berrady, R; Bono, W; El Hatimi, A; Gallouj, S; Khammar, Z; Lahlou, M; Lamchachti, L; Mernissi, FZ, 2012)
"In 40 to 50% of DBA patients, congenital abnormalities mostly in the cephalic area and in thumbs and upper limbs have been described."1.36Diamond-Blackfan anemia, ribosome and erythropoiesis. ( Da Costa, L; Leblanc, T; Mohandas, N; Moniz, H; Simansour, M; Tchernia, G, 2010)
"Cutaneous eruptive xanthomas are characteristics lesions of hyperlipidemia."1.36Eruptive neutrophilic xanthomas. ( Aldabagh, B; Bergfeld, W, 2010)
"However IFNalpha-induced systemic lupus erythematosus is a rare event."1.36Polyarthritis and anemia in a hemodialysis patient: systemic lupus erythematosus following treatment with interferon alpha. ( Galicier, L; Glotz, D; Peraldi, MN; Pillebout, E; Ripault, MP; Touzot, F; Touzot, M, 2010)
"Sneddon-Wilkinson disease or subcorneal pustular dermatosis (SPD) is a rare, benign inflammatory skin disorder of unknown etiology."1.35Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) occurring in association with nodal marginal zone lymphoma: a case report. ( Newman, J; Ratnarathorn, M, 2008)
"Retroperitoneal fibrosis is an often idiopathic disease that can cause compression of retroperitoneal structures such as the ureters."1.34[Fatigue, loss of appetite and anuria due to retroperitoneal fibrosis]. ( de Beus, E; Rensma, PL, 2007)
"The prednisone dose was reduced by a mean of 25% in these same 13 patients."1.31Experiences with leflunomide in solid organ transplantation. ( Brady, L; Chong, A; Huang, W; Jensik, S; Kottayil, A; Longstreth, J; Millis, M; Mital, D; Williams, JW, 2002)
"The National Comprehensive Cancer Network (NCCN) of cancer centers has recommended that all patients aged 70 years and older treated with CHOP or cytotoxic chemotherapy of comparable intensity should receive prophylactic G-CSF administration, and that the hemoglobin concentration be maintained at >or=12 g/dl in elderly patients undergoing chemotherapy."1.31Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy. ( Bokemeyer, C; Honecker, F; Kolb, G; Lipp, HP; Späth-Schwalbe, E; Wedding, U, 2002)
"We describe a patient with quiet systemic lupus erythematosus who developed a hypereosinophilic syndrome."1.30Hypereosinophilic syndrome presenting with diarrhoea and anaemia in a patient with systemic lupus erythematosus. ( Beerman, H; Markusse, HM; Schravenhoff, R, 1998)
"A kidney biopsy was consistent with Wegener's granulomatosis, and treatment with prednisone and cyclophosphamide was associated with normalization of serum calcium levels, improved renal function, a marked decrease in serum 1,25(OH)2D levels, and increased serum intact parathyroid hormone levels."1.29Case report: hypercalcemia with inappropriate 1,25-dihydroxyvitamin D in Wegener's granulomatosis. ( Findling, JW; Redlin, KC; Shaker, JL; Warren, GV, 1994)
"In three patients with advanced Hodgkin's disease treated with combination chemotherapy (MOPP) incorporating vincristine, and receiving at the same time a fixed daily dose of 8000 U of rHu-EPO subcutaneously for 10 to 15 days because of myelosuppressive anemia, myeloaspirates were performed one week before and 24 hours after the administration of vincristine."1.28Selective metaphasic arrest of erythroblasts by vincristine in patients receiving high doses of recombinant human erythropoietin for myelosuppressive anemia. ( Marmont, AM, 1992)
"93 children and adolescents with Crohn's disease have been studied."1.27[Crohn's disease in children and adolescents]. ( Bensoussan, A; Chouraqui, JP; Le Luyer, B; Morin, CL; Roy, CC; Weber, A, 1985)
"Anemia and leukopenia have been reported in sarcoidosis."1.27The anemia of sarcoidosis. ( Baughman, RP; Lower, EE; Martelo, OJ; Smith, JT, 1988)
"The patient died of respiratory failure because of infiltration of the lungs by malignant histiocytes."1.25Acute lymphoblastic leukemia terminating as histiocytic medullary reticulosis. ( Shreiner, DP, 1975)

Research

Studies (253)

TimeframeStudies, this research(%)All Research%
pre-1990153 (60.47)18.7374
1990's14 (5.53)18.2507
2000's35 (13.83)29.6817
2010's46 (18.18)24.3611
2020's5 (1.98)2.80

Authors

AuthorsStudies
Havlichek, D1
Choung, RS1
Murray, JA1
Qu, S2
Xu, Z2
Qin, T2
Li, B2
Pan, L2
Chen, J1
Yan, X1
Wu, J1
Zhang, Y3
Zhang, P1
Gale, RP3
Xiao, Z2
Tryfon, S1
Papadopoulou, E1
Psarros, G1
Agrafiotis, M1
Saroglou, M1
Chen, G2
Wu, D1
Li, MX1
Okello, CD1
Omoding, A1
Ddungu, H1
Mulumba, Y1
Orem, J1
Maeda, Y1
Nishimori, H1
Yoshida, I1
Hiramatsu, Y1
Uno, M1
Masaki, Y1
Sunami, K1
Masunari, T1
Nawa, Y1
Yamane, H1
Gomyo, H1
Takahashi, T1
Yano, T1
Matsuo, K1
Ohshima, K1
Nakamura, S1
Yoshino, T1
Tanimoto, M1
Nakayama, S1
Matsuda, M1
Adachi, T1
Sueda, S1
Ohashi, Y1
Awaji, S1
Hashimoto, S1
Matsumura, I1
Saito, T1
Okamura, A1
Inoue, J1
Makiura, D1
Doi, H1
Yakushijin, K1
Matsuoka, H1
Sakai, Y1
Ono, R1
Quintanilla-González, L1
Torres-Villalobos, G1
Hinojosa-Azaola, A1
Komrokji, RS1
Al Ali, NH1
Padron, E1
Cogle, C1
Tinsley, S1
Sallman, D1
Lancet, JE1
Lis, AF1
Ge, YL1
Liu, CH1
Zhang, Q1
Wang, YM1
Wang, N1
Zhang, HF1
Chen, QC1
Chen, Y1
Li, WQ1
Zhu, XY1
Fu, AS1
Puente, J1
González-Del-Alba, A1
Sala-Gonzalez, N1
Méndez-Vidal, MJ1
Pinto, A1
Rodríguez, Á1
Cuevas Sanz, JM1
Muñoz Del Toro, JR1
Useros Rodríguez, E1
García García-Porrero, Á1
Vázquez, S1
Hou, S1
Hegerova, LT1
Lin, Y1
Papadopoulou, V1
Ioannou, S1
Levidou, G1
Variami, E1
Kouzis, P1
Siakantaris, M1
Michaelson, MD1
Oudard, S1
Ou, YC1
Sengeløv, L1
Saad, F1
Houede, N1
Ostler, P1
Stenzl, A1
Daugaard, G1
Jones, R1
Laestadius, F1
Ullèn, A1
Bahl, A1
Castellano, D1
Gschwend, J2
Maurina, T1
Chow Maneval, E1
Wang, SL1
Lechuga, MJ1
Paolini, J1
Chen, I1
Ruan, J1
Gregory, SA1
Christos, P1
Martin, P1
Furman, RR1
Coleman, M1
Leonard, JP1
Heidenreich, A2
Bracarda, S1
Mason, M1
Ozen, H1
Sengelov, L1
Van Oort, I1
Papandreou, C1
Fossa, S1
Hitier, S1
Climent, MA1
Tefferi, A4
Hudgens, S1
Mesa, R1
Verstovsek, S4
Passamonti, F2
Cervantes, F4
Rivera, C1
Tencer, T1
Khan, ZM1
Cheng, J1
Talamo, G1
Malysz, J1
Ochmann, M1
Lamy, T1
Loughran, TP1
Daver, N1
Shastri, A1
Kadia, T1
Newberry, K1
Pemmaraju, N1
Jabbour, E1
Zhou, L1
Pierce, S1
Cortes, J2
Kantarjian, H1
Xu, J1
Fang, L1
Zhang, H1
Hu, N1
Watson, P1
Brennan, A1
Birch, H1
Fang, H1
Petri, M1
Hong, J1
Woo, HS1
Kim, H1
Ahn, HK1
Sym, SJ1
Park, J1
Ahn, JY1
Cho, EK1
Shin, DB1
Lee, JH2
Hernández-Boluda, JC1
Martínez-Trillos, A1
García-Gutiérrez, V1
Ferrer-Marín, F1
Xicoy, B1
Alvarez-Larrán, A1
Kerguelen, A1
Barba, P1
Gómez, M1
Herrera, JC1
Correa, JG1
Bellakhal, S1
Ben Kaab, B1
Teyeb, Z1
Souissi, A1
Derbel, F1
Douggui, MH1
Adams, HJ1
de Klerk, JM1
Fijnheer, R1
Heggelman, BG1
Dubois, SV1
Nievelstein, RA1
Kwee, TC1
Adam, Z1
Pour, L1
Krejčí, M1
Ševčíková, S1
Pourová, E1
Ševčíková, E1
Král, Z1
Mayer, J1
Lakkaraja, M1
Jin, JC1
Manotas, KC1
Vinograd, CA1
Ferd, P1
Gabor, J1
Wissert, M1
Berkowitz, RL1
McFarland, JG1
Bussel, JB1
Charpentier, AM1
Friedman, DL1
Wolden, S1
Schwartz, C1
Gill, B1
Sykes, J1
Albert-Green, A1
Kelly, KM1
Constine, LS1
Hodgson, DC1
Popp, A1
Jurcuţ, C1
Balaban, DV1
Șotcan, M1
Laurila, K1
Jinga, M1
Xie, Y1
Guo, JQ1
Hua, Y1
Zhao, WH1
Sun, Q1
Lu, XT1
Lu, J1
Huang, SY1
Qiu, L1
Lee, JJ1
Liu, T1
Yoon, SS1
Kim, K1
Shen, ZX1
Eom, HS1
Chen, WM1
Min, CK1
Kim, HJ1
Lee, JO1
Kwak, JY1
Yiu, W1
Ervin-Haynes, A1
Hulin, C1
Facon, T1
Ratnarathorn, M1
Newman, J1
Santoro, RC1
Prejanò, S1
Barosi, G1
Roboz, GJ1
Gisslinger, H1
Paquette, RL1
Rivera, CE1
Deeg, HJ1
Thiele, J1
Kvasnicka, HM1
Vardiman, JW1
Bekele, BN1
Mesa, RA2
Kantarjian, HM2
Quintás-Cardama, A1
Manshouri, T1
Thomas, D1
Ravandi, F1
Garcia-Manero, G1
Ferrajoli, A1
Bueso-Ramos, C1
Sternberg, CN1
Petrylak, DP1
Sartor, O1
Witjes, JA1
Demkow, T1
Ferrero, JM1
Eymard, JC1
Falcon, S1
Calabrò, F1
James, N1
Bodrogi, I1
Harper, P1
Wirth, M2
Berry, W1
Petrone, ME1
McKearn, TJ1
Noursalehi, M1
George, M1
Rozencweig, M1
Malyszko, J1
Malyszko, JS1
Mysliwiec, M1
Jöbsis, JJ1
Fijnvandraat, K1
Stapel, SO1
Bouts, AH1
Touzot, M1
Touzot, F1
Galicier, L1
Ripault, MP1
Peraldi, MN1
Glotz, D1
Pillebout, E1
Engert, A3
Josting, A2
Haverkamp, H1
Villalobos, M1
Lohri, A1
Sökler, M1
Zijlstra, J1
Sturm, I1
Topp, MS1
Rank, A1
Zenz, T1
Vogelhuber, M1
Nogova, L1
Borchmann, P1
Fuchs, M1
Flechtner, HH1
Diehl, V2
Aldabagh, B1
Bergfeld, W1
Bauer, K1
Herbst, C1
Brillant, C1
Monsef, I1
Kluge, S1
Skoetz, N1
Da Costa, L1
Moniz, H1
Simansour, M1
Tchernia, G1
Mohandas, N1
Leblanc, T1
El Halim Mohamed Abu Hamar, A1
Mansour, S1
El Shebiney, M1
El Bary, NM1
Sadaka, E1
Maria, A1
Gerecitano, J1
Portlock, C1
Hamlin, P1
Moskowitz, CH1
Noy, A1
Straus, D1
Schulman, P1
Dumitrescu, O1
Sarasohn, D1
Pappanicholaou, J1
Iasonos, A1
Zhang, Z1
Mo, Q1
Horanlli, E1
Rojas, CN1
Zelenetz, AD1
O'Connor, OA1
Merli, F2
Luminari, S2
Rossi, G1
Mammi, C2
Marcheselli, L2
Tucci, A1
Ilariucci, F1
Chiappella, A1
Musso, M1
Di Rocco, A1
Stelitano, C3
Alvarez, I1
Baldini, L3
Mazza, P1
Salvi, F1
Arcari, A1
Fragasso, A1
Gobbi, PG2
Liberati, AM1
Federico, M2
Morabito, F1
Hohaus, S1
Gentile, M1
Montanini, A1
La Sala, A1
Scalone, R1
Voso, MT1
Iannitto, E1
Gobbi, P1
Berrady, R1
Baybay, H1
Khammar, Z1
Lahlou, M1
Lamchachti, L1
Gallouj, S1
El Hatimi, A1
Mernissi, FZ1
Bono, W1
Pönisch, W1
Andrea, M1
Wagner, I1
Hammerschmidt, D1
Kreibich, U1
Schwarzer, A1
Zehrfeld, T1
Schwarz, M1
Winkelmann, C1
Petros, S1
Bachmann, A1
Lindner, T1
Niederwieser, D1
Spina, M1
Balzarotti, M1
Uziel, L1
Ferreri, AJ1
Fratino, L1
Magagnoli, M1
Talamini, R1
Giacalone, A1
Ravaioli, E1
Chimienti, E1
Berretta, M1
Lleshi, A1
Santoro, A1
Tirelli, U1
Nassiri, M1
Robertson, MJ1
Hertzberg, L1
Czader, MB1
Scholz, HJ1
Rogenhofer, S1
Arsov, C1
Retz, M1
Müller, SC1
Albers, P1
Steiner, U1
Miller, K1
Heinrich, E1
Trojan, L1
Volkmer, B1
Honecker, F2
Bokemeyer, C2
Keck, B1
Otremba, B1
Ecstein-Fraisse, E1
Pfister, D1
Rapp, M2
Berg, C1
Knoepfle, G1
Müller, AM2
Bartmann, P1
Iriyama, N1
Takahashi, H1
Hatta, Y1
Miura, K1
Kobayashi, Y1
Kurita, D1
Hirabayashi, Y1
Hojo, A1
Kodaira, H1
Yagi, M1
Kiso, S1
Uchino, Y1
Nakagawa, M1
Kusuda, M1
Kobayashi, S1
Horikoshi, A1
Kura, Y1
Yamazaki, T1
Sawada, U1
Takeuchi, J1
Morrow, TJ1
Volpe, S1
Gupta, S1
Tannous, RE1
Fridman, M1
Steensma, DP1
Pardanani, A1
Li, CY1
Elliott, M1
Kaufmann, SH1
Wiseman, G1
Gray, LA1
Schroeder, G1
Reeder, T1
Zeldis, JB1
Cavallo, R1
Merlino, C1
Re, D1
Bollero, C1
Bergallo, M1
Lembo, D1
Musso, T1
Leonardi, G1
Segoloni, GP1
Ponzi, AN1
Sieber, M1
Bredenfeld, H1
Reineke, T1
Rueffer, U1
Koch, T1
Naumann, R1
Boissevain, F1
Koch, P1
Worst, P1
Soekler, M1
Eich, H1
Müller-Hermelink, HK1
Franklin, J1
Paulus, U1
Wolf, J1
Meier, P1
Gilabert, C1
Burnier, M1
Blanc, E1
Malliti, M1
Junot, H1
Fievet, MH1
Gabarre, J1
Taright, N1
Vernant, JP1
Thuillier, A1
SUSSMAN, LN1
DORDICK, JR1
POLLI, E1
CROSTI, PF1
CARRARA, PM1
STEFANINI, M1
MARTINO, NB1
REMY, D1
BROCKHAUS, L1
LICHTMAN, HC1
RABINER, SF1
SHIELDS, GS1
PLOTKIN, N1
LEVERE, R1
GARRAHAN, JP2
ALBORES, JM1
SENET, RE1
CEDRATO, AE1
CANTONI, L1
CICONALI, M1
SCALTRINI, GC1
VOLTA, A1
SAXENA, KM1
SARASWAT, KD1
BRUZZESE, L1
IULIANI, G1
ROGER, S1
FROST, JW1
GOLDWEIN, MI1
PITNEY, WR1
O'SULLIVAN, WJ1
OWEN, JA1
PARRY, EH1
KILPATRICK, GS1
HARDISTY, RM1
OSTERGAARD KRISTENSEN, HP4
FRIIS, T4
JEUNE, M1
GERMAIN, D1
HUMBERT, G1
NIVELON, JL1
CROLLE, G1
COSCIA, GC1
BASSO, F1
SEIP, M1
KURTIDES, ES1
ALT, HL1
LETMAN, H1
JANDL, JH1
RITZ, ND2
HABER, A1
WEINER, AA1
IMERSLUND, O1
BJORNSTAD, P1
BRUS, I1
PARANDE, AS1
JAIN, KL1
RANLOV, P1
VIDEBAEK, A1
EMPARANZA, E1
HASBUN, SJ1
VILDOSOLA, J1
OLCESE, A1
FAIGEL, HC1
KUHN, E1
KOHN, R1
CHAKRABARTI, R1
FEARNLEY, GR1
HOCKING, ED1
ROSNER, F3
SUSSMAN, SN1
GALLINELLI, R1
TRALDI, A1
KEHOE, EL1
NEWCOMER, KL1
FARRERASVALENTI, P1
ROZMAN, C2
WOESSNER, S1
MYKHAMEDZIANOVA, GS1
MASSIMO, L2
RAINERO, L1
MELVIN, KE1
DAVIDSON, JN1
BURNINGHAM, RA1
RESTREPO, A1
PUGH, RP1
BROWN, EB1
SCHLOSSMAN, SF1
KHURI, PD1
LESSNER, HE1
HARRINGTON, WJ1
SZEKELY, K1
LABRAM, C1
JACOTTET, M1
ELEFANT, E1
JEKLEROVA, J1
JANELE, J1
DUHAMEL, G1
MARCHAL, G1
MILLS, SD1
KYLE, RA3
HALLENBECK, GA1
PEASE, GL1
CREE, IC1
HOLLEY, HL1
HOGAN, RS1
BARTOLOZZI, G1
PAVARI, E1
GUAZZELLI, C1
MARIANELLI, L1
O'LEARY, JA1
BODIAN, M1
SHELDON, W1
LIGHTWOOD, R1
ISRAELS, LG1
ERSLEV, AJ1
GROSS, S1
NEWMAN, AJ1
PECORELLA, F1
AZEN, EA1
CLATANOFF, DV1
EBIHARA, T1
ISHIKAWA, A1
YAMBE, D1
WOODLIFF, HJ1
KAKULAS, BA1
BELLOT, SM1
ROSS, JD1
ROSENBAUM, E1
KEENEY, EL1
ROSSI, V1
BIANCHINI, E1
MAINWARING, D1
KEIDAN, SE1
KOZINN, PJ1
MOSS, AH1
KAUFMAN, A1
MCANDREW, GM1
BETKE, K1
HEINE, KM1
HERRMANN, H1
STOBBE, H1
KENNEDY, BJ1
DUNEA, G1
NAKAMOTO, S1
STRAFFON, RA1
FIGUEROA, JE1
VERSACI, AA1
SHIBAGAKI, M1
KOLFF, WJ1
RETIEF, FP1
WASSERMANN, HP1
HOFMEYER, NG1
ROSNER, P1
HAUSSER, E1
RUHRMANN, G1
BEAL, RW1
KRONENBERG, H1
FIRKIN, BG1
HERSKO, C1
IZAK, G1
GOLDSTEIN, C1
PECHET, L1
MACLACHLAN, MJ1
RODNAN, GP1
COOPER, WM1
FENNELL, RH1
EDWARDS, CL1
GENGOZIAN, N1
LUEBECK, I1
SUCKOW, KL1
HEINE, K1
GRUENWALD, H1
TAUB, RN1
WONG, FM1
KIOSSOBLOU, KA1
DAMESHEK, W1
MEHRA, SK1
DAVIES, DM1
BELL, SM1
LOGE, JP1
DOBBS, CE1
HUCZEK-GLEBOCKI, J1
OSTERCZY, Z1
LINSK, JA1
MURRAY, CK1
MOODY, EA1
MOVITT, ER1
MANGUM, JF1
JUNG, ED1
PORTER, WR1
Owais, Z1
Dane, J1
Cumming, CG1
Basi, S1
Schulman, G1
Fogo, AB1
Callan, MB1
Preziosi, D1
Mauldin, E1
Pan, ZH1
Huang, HQ1
Lin, XB1
Xia, YF1
Xia, ZJ1
Peng, YL1
Cai, QQ1
Lin, TY1
Jiang, WQ1
Guan, ZZ1
Johnston, KL1
Farnen, JP1
Manske, BR1
Go, RS1
Cheung, PP1
Richards, G1
de Beus, E1
Rensma, PL1
Vilá, LM1
Molina, MJ1
Scheinfeld, N1
Schecter, JM1
Mears, JG1
Alobeid, B1
Gaglio, PJ1
Doganis, D1
Baka, M1
Pourtsidis, A1
Bouhoutsou, D1
Varvoutsi, M1
Stamos, G1
Anastasiou, N1
Androulakakis, E1
Vasilatou-Kosmidis, H1
Errante, D1
Bianco, A1
Aversa, SML1
Salvagno, L1
Garay, G1
Milone, J1
Dibar, E1
Pavlovsky, S1
Kvicala, R1
Sackmann Muriel, F1
Montres Varela, D1
Eppinger-Helft, M1
Alfinito, F1
Formisano, S1
Rotoli, B1
Belisario, A1
D'Antuono, G1
Modiano, A1
Pascual, JF1
Molina, M1
Lopez, J1
Barista, I1
Tekuzman, G1
Firat, D1
Baltali, E1
Kansu, E1
Kars, A1
Ozisik, Y1
Ruacan, S1
Uzunalimoğlu, B1
Karaağaoğlu, E1
Weiss, LM1
Gonzalez, E1
Miller, SB1
Agudelo, CA1
Witzig, TE1
Weitz, JJ1
Lundberg, JH1
Shaker, JL1
Redlin, KC1
Warren, GV1
Findling, JW1
Moltyaner, Y1
Tenenbaum, J1
Zlatanic, J1
Korelitz, BI1
Wisch, N1
Kim, P1
Ammirati, M1
Schwarz, S1
Gruenstein, S1
Lipsey, L1
Markusse, HM1
Schravenhoff, R1
Beerman, H1
Kettaneh, A1
Hayem, G1
Palazzo, E1
Debandt, M1
Lebail-Darné, JL1
Roux, S1
Kahn, MF1
Meyer, O1
Witzens, M1
Egerer, G1
Stahl, D1
Werle, E1
Goldschmidt, H1
Haas, R1
Hamasaki, A1
Ishii, K1
Yamaguchi, K1
Sunamoto, M1
Ozaki, H1
Yanagita, M1
Wakatsuki, Y1
Horiuchi, H1
Nakahata, Y1
Kita, T1
San Miguel, JF1
Bladé Creixenti, J1
García-Sanz, R1
Heilborn, JD1
Ståhle-Bäckdahl, M1
Albertioni, F1
Vassilaki, I1
Peterson, C1
Stephansson, E1
Bueno, J2
Zuazu, J1
Villalba, T1
Julià, A1
Ghirardelli, ML1
Avanzini, P1
Quarta, G1
Broglia, C1
Loni, C1
Silingardi, V1
Ascari, E2
Hoyt, PG1
Gill, MS1
Angel, KL1
Gaunt, SD1
Dial, SM1
Landreneau, RM1
Messick, JB1
Berent, LM1
Ehrhart, EJ1
Wasmer, CC1
Emre, S1
Bilge, I1
Sirin, A1
Kilicaslan, I1
Nayir, A1
Oktem, F1
Uysal, V1
Colombi, M1
Guffanti, A1
Alietti, A1
Latargia, ML1
Vener, C1
Maiolo, AT1
Niitsu, N1
Iijima, K1
Williams, JW1
Mital, D1
Chong, A1
Kottayil, A1
Millis, M1
Longstreth, J1
Huang, W1
Brady, L1
Jensik, S1
Wedding, U1
Späth-Schwalbe, E1
Lipp, HP1
Kolb, G1
Vivancos, J1
Vila, M1
Serra, A1
Loscos, J1
Anguita, A1
Rea, TH1
Ben Taarit, C1
Turki, S1
Ben Maïz, H1
Cotter, SM1
Wechsler, HL1
Stavrides, A1
Sawitsky, A1
Rai, KR1
Glidewell, O1
Silver, RT2
Newton, PA1
Shreiner, DP1
Alexanian, R1
Balcerzak, S1
Bonnet, JD2
Gehan, EA2
Haut, A1
Hewlett, JS2
Monto, RW1
Silverstein, MN2
Ghose, MK1
Shensa, S1
Lerner, PI1
Marmont, AM1
Schiller, JH1
Hawkins, MJ1
O'Connell, MJ1
Sielaff, K1
Borden, EC1
López-Guillermo, A1
Ribera, JM1
Feliu, E1
Florensa, L1
Le Luyer, B1
Morin, CL1
Roy, CC1
Weber, A1
Chouraqui, JP1
Bensoussan, A1
Tejani, A1
Butt, KM1
Khawar, MR1
Hong, JH1
Fusi, M1
Pomrantz, A1
Lower, EE1
Smith, JT1
Martelo, OJ1
Baughman, RP2
Montserrat, E1
Alcalá, A1
Parody, R1
Domingo, A1
García-Conde, J1
Ferrán, C1
Sanz, MA1
Giralt, M1
Rubio, D1
Balaban, EP1
Buchanan, GR1
Graham, M1
Frenkel, EP1
Dewulf, E1
Vielle, G1
Hongque, MP1
Arianoff, AA1
Connor, B1
Warrell, DA1
Davidson, NM1
Omerod, LD1
Pope, HM1
Watkins, BJ1
Greenwood, BM1
Ried, HA1
Schubert, JC1
Martin, H1
Biggs, JC1
Adam, JE1
Vivien, P1
Gastard, J1
Allannic, H1
Morel, H1
Loussouarn, J1
Foley, HT1
Bennett, JM1
Carbone, PP1
Hoogstraten, B1
Ansell, BM1
Bywaters, EG1
Bodey, GP1
Coltman, CA1
Freireich, EJ1
Haut, AB1
McCredit, KB1
Saiki, JH1
Wilson, HE1
Fairley, GH1
Robertson, JH1
Crozier, EH1
Hollinger, M1
Burton, JL1
Greaves, MW1
Perugini, S1
Fontana, G1
Murphy, GP1
Mirand, EA1
Grace, JT1
Fine, RN1
Korsch, BM1
Stiles, Q1
Riddell, H1
Edelbrock, HH1
Brennan, LP1
Grushkin, CM1
Lieberman, E1
Greenberg, LH1
Wong, S1
Richardson, AP1
Dollinger, MR1
Honetz, N1
Krasilnikoff, PA1
Lee, SL2
Kaufmann, RW1
Schechter, GP1
McFarland, W1
Dyrkorn, K1
Magnus, EM1
Siering, H1
Eitner, K1
Aasved, H1
Jones, FL1
Blodgett, RC1
Ruberman, W1
Glasberg, S1
Johnston, DH1
Duverne, J1
Volle, H1
Demilly, J1
Mantout, B1
Szreder, W1
Mitus, WJ1
Coleman, N1
Kiossoglou, KA1
Waaler, G1
Lévèque, B1
Debauchez, C1
Deflandre, L1
Marie, J1
Krupa, B1
Muszkowska-Penson, J1
Rynkiewicz, H1
Horoszek, S1
Arndt, R1

Clinical Trials (18)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma[NCT05996185]Phase 236 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma[NCT03586999]Phase 1/Phase 218 participants (Actual)Interventional2018-11-07Active, not recruiting
An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Androgen Independent Metastatic Prostate Cancer Patients With Rising PSA[NCT00106418]Phase 235 participants (Actual)Interventional2003-05-07Completed
A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen[NCT00676650]Phase 3873 participants (Actual)Interventional2008-07-31Terminated (stopped due to Study A6181120 was prematurely discontinued due to futility on 27 September 2010. No new or unexpected safety issues were identified.)
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial[NCT03003325]Phase 2127 participants (Actual)Interventional2017-02-02Completed
A Phase II, Prospective, Open Label Study (PO-MMM-PI-0011) to Determine the Safety and Efficacy of Pomalidomide (CC-4047) in Subjects With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis (PMF; Post-PV MF, or Post-ET MF)[NCT00946270]Phase 270 participants (Actual)Interventional2009-07-22Completed
A Randomized Multicenter Trial of Antenatal Treatment of Alloimmune Thrombocytopenia[NCT00194987]Phase 2/Phase 3102 participants (Actual)Interventional2001-04-30Completed
A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, an[NCT00689936]Phase 31,623 participants (Actual)Interventional2008-08-21Completed
A Phase I Study of Single-centre, Open-label Clinical Trial to Evaluate HG146 Capsule in the Treatment of Relapsed and Refractory Multiple Myeloma[NCT03710915]Phase 13 participants (Actual)Interventional2019-01-12Terminated (stopped due to Company decision)
Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF)[NCT00352794]Phase 240 participants (Actual)Interventional2006-07-07Completed
Phase I/II, Open-Label Study to Determine Safety and Efficacy of Sotatercept (ACE-011) in Adults With Red Blood Cell Transfusion- Dependent Diamond Blackfan Anemia[NCT01464164]Phase 1/Phase 219 participants (Actual)Interventional2012-01-31Terminated (stopped due to Supporter terminated the study due to no active patients (secondary to travel restrictions due to COVID).)
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)[NCT00295932]Phase 1/Phase 279 participants (Actual)Interventional2005-12-13Completed
A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL)[NCT01148446]Phase 3226 participants (Actual)Interventional2003-01-31Completed
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine[NCT00001533]Phase 125 participants Interventional1996-09-30Completed
Phase III, Prospective, Open Label, Multicenter, Randomized Trial of Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone as First Line Therapy in Myeloma Patients Aged >65.[NCT00232934]Phase 3400 participants Interventional2002-01-31Completed
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)[NCT00779883]Phase 19 participants (Actual)Interventional2006-06-30Completed
A Phase 1B Extension Trial to Allow Repeat Dosing of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Subjects Previously Treated in MDACC Protocol 2004-0914[NCT00783588]Phase 14 participants (Actual)Interventional2007-05-31Completed
Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839]Phase 221 participants (Actual)Interventional2012-02-22Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Overall Survival (OS)

OS is the duration from randomization to death. For participants who were alive, overall survival was censored at the last contact. OS (in months) calculated as (date of death minus [-] date of randomization plus [+] 1) divided (/) 30.4. (NCT00676650)
Timeframe: Baseline up to 32 months

Interventionmonths (Median)
Sunitinib and Prednisone13.1
Placebo and Prednisone11.8

Percent of Participants With Objective Response (OR)

OR defined as the percent (%) of participants with confirmed Complete Response (CR) (disappearance of all target lesions) or Partial Response (PR) (>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions) according to Response Evaluation Criteria in Solid Tumors (RECIST), relative to the full analysis population. Confirmed responses were those that persist on repeat imagining study >= 4 weeks after initial documentation of response. (NCT00676650)
Timeframe: Baseline, every 8 weeks up to 123 weeks

Interventionpercentage of participants (Number)
Sunitinib and Prednisone6.1
Placebo and Prednisone1.8

Progression-Free Survival (PFS)

PFS is the period from randomization until disease progression or death on study. PFS is censored on the date of last tumor assessment documenting absence of progressive disease. PFS (weeks) calculated as (first event date - randomization date + 1)/7.02 (NCT00676650)
Timeframe: Baseline, every 8 weeks up to 123 weeks

Interventionweeks (Median)
Sunitinib and Prednisone24.1
Placebo and Prednisone17.9

Number of Participants With Best Overall Response

Primary endpoint is best overall response. An evaluable subject classified as a treatment success for the primary endpoint if the subject's best overall response is clinical improvement (CI) as determined by International Working Group Criteria over the first 6 cycles of study treatment. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis - Clinical improvement (CI) in anemia 1/ A minimum 20g/L increase in hemoglobin level or 2. becoming transfusion independent for at least 8 week duration. (NCT00946270)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Group 1 CC-40470
Group 23
Group 3 CC-4047 + Prednisone6

Intracranial Hemorrhage: Number Occurring in Fetuses and Newborns of Mothers in Study

number of ICH assessed by fetal and neonatal ultrasound with MRI back up most commonly in utero so range from 20-40 weeks fo gestation (NCT00194987)
Timeframe: time of ICH (range 20-40 wks)

Interventionnumber of newborns with ICH (Number)
IVIG 1g/kg Twice Per Week0
IVIG 1g/k/Week and Prednisone 0.5 mg/kg/Day0

Number of Fetal Platelet Counts > 50,000/uL

Number of Fetal Platelet Counts > 50,000/uL Among Those Who Underwent Fetal Blood Sampling and Had a Fetal Platelet Count Determined (NCT00194987)
Timeframe: 32 +/- 2 weeks

Interventionnumber newborns with >50,000 pats (Number)
IVIG 1g/kg Twice Per Week44
IVIG 1g/k/Week and Prednisone 0.5 mg/kg/Day43

Number of Newborns With a Birth Platelet Count > 50,000/uL

this uses the birth platelet count of the fetuses from the study when they are born (NCT00194987)
Timeframe: 32-40 weeks (the endpoint is the birth which is not at the same number of weeks for all of the babies. This is why the weeks are not listed specifically eg week 40

Interventionnumber of newborns with >50,000 pets (Number)
IVIG 1g/kg Twice Per Week48
IVIG 1g/k/Week and Prednisone 0.5 mg/kg/Day47

Kaplan Meier Estimates for Time to Second-line Anti-myeloma Treatment (AMT)

Time to second-line anti-myeloma therapy was defined as time from randomization to the start of another non-protocol anti-myeloma therapy. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 23.0 months

Interventionmonths (Median)
Lenalidomide and Low-Dose Dexamethasone (Rd)39.1
Lenalidomide and Dexamethasone Rd1828.5
Melphalan + Prednisone + Thalidomide (MPT)26.7

Kaplan Meier Estimates of Duration of Myeloma Response as Determined by an Investigator Assessment at Time of Final Analysis

Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median follow-up for responders was 19.9 months

Interventionmonths (Median)
Lenalidomide and Low-Dose Dexamethasone (Rd)31.5
Lenalidomide and Dexamethasone Rd1821.5
Melphalan + Prednisone + Thalidomide (MPT)22.1

Kaplan Meier Estimates of Duration of Myeloma Response as Determined by the IRAC

Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median follow-up for responders was 20.1 months

Interventionmonths (Median)
Lenalidomide and Low-Dose Dexamethasone (Rd)35.0
Lenalidomide and Dexamethasone Rd1822.1
Melphalan + Prednisone + Thalidomide (MPT)22.3

Kaplan Meier Estimates of Overall Survival at the Time of Final Analysis (OS)

Overall survival was defined as the time between randomization and death. Participants, who died, regardless of the cause of death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the participant was known to be alive. (NCT00689936)
Timeframe: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 48.3 months

Interventionmonths (Median)
Lenalidomide and Low-Dose Dexamethasone (Rd)59.1
Lenalidomide and Dexamethasone Rd1862.3
Melphalan + Prednisone + Thalidomide (MPT)49.1

Kaplan Meier Estimates of Time to Second Line Therapy AMT at the Time of Final Analysis

Time to second-line anti-myeloma therapy is defined as time from randomization to the start of another non-protocol anti-myeloma therapy. Those who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of date 21 January 2016; median follow-up for all participants was 23.0 months

Interventionmonths (Median)
Lenalidomide and Low-Dose Dexamethasone (Rd)36.7
Lenalidomide and Dexamethasone Rd1828.5
Melphalan + Prednisone + Thalidomide (MPT)26.7

Kaplan Meier Estimates of Time to Treatment Failure (TTF)

TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by IRAC based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 16.1 months.

Interventionmonths (Median)
Lenalidomide and Low-Dose Dexamethasone (Rd)16.9
Lenalidomide and Dexamethasone Rd1817.2
Melphalan + Prednisone + Thalidomide (MPT)14.1

Kaplan Meier Estimates of Time to Treatment Failure (TTF) at the Time of Final Analysis

TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by the investigators assessment based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death. (NCT00689936)
Timeframe: From date of randomization until the data cut-off date of 21 January 2016; median follow up for all participants was 16.1 months.

Interventionmonths (Median)
Lenalidomide and Low-Dose Dexamethasone (Rd)16.9
Lenalidomide and Dexamethasone Rd1817.2
Melphalan + Prednisone + Thalidomide (MPT)14.1

Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis

PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's). (NCT00689936)
Timeframe: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months

Interventionmonths (Median)
Lenalidomide and Low-Dose Dexamethasone (Rd)26.0
Lenalidomide and Dexamethasone Rd1821.0
Melphalan + Prednisone + Thalidomide (MPT)21.9

Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)

PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's). (NCT00689936)
Timeframe: From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.

Interventionmonths (Median)
Lenalidomide and Low-Dose Dexamethasone (Rd)25.5
Lenalidomide and Dexamethasone Rd1820.7
Melphalan + Prednisone + Thalidomide (MPT)21.2

Percentage of Participants With a Myeloma Response by Adverse Risk Cytogenetic Risk Category Based on IRAC Review.

Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

InterventionPercentage of participants (Number)
Lenalidomide and Low-Dose Dexamethasone (Rd)70.0
Lenalidomide and Dexamethasone Rd1869.7
Melphalan + Prednisone + Thalidomide (MPT)58.2

Percentage of Participants With a Myeloma Response by Favorable Hyperdiploidy Risk Cytogenetic Risk Category Based on IRAC Review

Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

Interventionpercentage of participants (Number)
Lenalidomide and Low-Dose Dexamethasone (Rd)80.4
Lenalidomide and Dexamethasone Rd1881.6
Melphalan + Prednisone + Thalidomide (MPT)70.6

Percentage of Participants With a Myeloma Response by Normal Risk Cytogenetic Risk Category Based on IRAC Review

Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

Interventionpercentage of particpants (Number)
Lenalidomide and Low-Dose Dexamethasone (Rd)80.4
Lenalidomide and Dexamethasone Rd1874.8
Melphalan + Prednisone + Thalidomide (MPT)61.0

Percentage of Participants With a Myeloma Response by Uncertain Risk Cytogenetic Risk Category Based on IRAC Review

Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

Interventionpercentage of participants (Number)
Lenalidomide and Low-Dose Dexamethasone (Rd)60.5
Lenalidomide and Dexamethasone Rd1876.8
Melphalan + Prednisone + Thalidomide (MPT)57.5

Percentage of Participants With an Objective Response After Second-line Anti-myeloma Treatment at the Time of Final Analysis

Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

Interventionpercentage of participants (Number)
Lenalidomide and Low-Dose Dexamethasone (Rd)46.2
Lenalidomide and Dexamethasone Rd1853.1
Melphalan + Prednisone + Thalidomide (MPT)45.7

Percentage of Participants With an Objective Response Based on Investigator Assessment at Time of Final Analysis

Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

Interventionpercentage of participants (Number)
Lenalidomide and Low-Dose Dexamethasone (Rd)80.7
Lenalidomide and Dexamethasone Rd1878.6
Melphalan + Prednisone + Thalidomide (MPT)67.5

Percentage of Participants With an Objective Response Based on IRAC Review

Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined as: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

Interventionpercentage of participants (Number)
Lenalidomide and Low-Dose Dexamethasone (Rd)75.1
Lenalidomide and Dexamethasone Rd1873.4
Melphalan + Prednisone + Thalidomide (MPT)62.3

Time to First Response Based on the Investigator Assessment at the Time of Final Analysis

The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria assessed by the investigator. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm.

Interventionmonths (Median)
Lenalidomide and Low-Dose Dexamethasone (Rd)1.8
Lenalidomide and Dexamethasone Rd181.8
Melphalan + Prednisone + Thalidomide (MPT)2.8

Time to First Response Based on the Review by the IRAC

The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

Interventionmonths (Median)
Lenalidomide and Low-Dose Dexamethasone (Rd)1.8
Lenalidomide and Dexamethasone Rd181.8
Melphalan + Prednisone + Thalidomide (MPT)2.8

Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Scale is scored between 0 and 100, with a high score indicating a higher level of appetite loss. Negative change from Baseline values indicate improvement in appetite and positive values indicate worsening of appetite. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd182.9-3.3-8.6-6.4-5.1-7.5
Lenalidomide and Low-Dose Dexamethasone (Rd)1.3-5.9-9.8-7.3-8.1-1.0
Melphalan + Prednisone + Thalidomide (MPT)1.0-6.2-13.5-10.5-12.2-2.6

Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1, (Baseline) then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd18-1.71.80.9-1.2-2.8-2.6
Lenalidomide and Low-Dose Dexamethasone (Rd)-1.2-0.7-0.9-1.6-2.2-4.9
Melphalan + Prednisone + Thalidomide (MPT)-1.8-1.5-0.3-0.6-0.7-7.1

Change From Baseline in the EORTC QLQ-C30 Constipation Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Scale is scored between 0 and 100, with a high score indicating a higher level of constipation. Negative change from Baseline values indicate improvement in constipation and positive values indicate worsening of constipation. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd186.30.0-5.1-5.2-5.9-7.5
Lenalidomide and Low-Dose Dexamethasone (Rd)8.31.8-2.4-2.4-4.5-7.9
Melphalan + Prednisone + Thalidomide (MPT)18.413.96.83.70.0-2.2

Change From Baseline in the EORTC QLQ-C30 Diarrhea Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarrhea Scale is scored between 0 and 100, with a high score indicating a higher level of diarrhea. Negative change from Baseline values indicate improvement in diarrhea and positive values indicate worsening of diarrhea. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd182.33.46.09.110.96.4
Lenalidomide and Low-Dose Dexamethasone (Rd)3.83.78.211.814.810.8
Melphalan + Prednisone + Thalidomide (MPT)-0.6-2.4-2.2-2.5-1.7-0.5

Change From Baseline in the EORTC QLQ-C30 Dyspnea Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd183.6-1.9-2.9-1.62.90.8
Lenalidomide and Low-Dose Dexamethasone (Rd)0.9-0.8-2.3-3.5-1.8-1.0
Melphalan + Prednisone + Thalidomide (MPT)4.22.00.1-1.60.47.8

Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd180.13.95.84.93.13.7
Lenalidomide and Low-Dose Dexamethasone (Rd)0.63.84.64.65.82.6
Melphalan + Prednisone + Thalidomide (MPT)1.02.15.55.15.1-0.0

Change From Baseline in the EORTC QLQ-C30 Fatigue Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd184.4-3.4-5.9-2.30.1-1.6
Lenalidomide and Low-Dose Dexamethasone (Rd)2.6-2.5-3.7-4.3-3.10.3
Melphalan + Prednisone + Thalidomide (MPT)2.8-1.8-4.5-3.9-4.32.7

Change From Baseline in the EORTC QLQ-C30 Financial Difficulties Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Difficulties Scale is scored between 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicate improvement in financial difficulties and positive values indicate worsening of financial difficulties. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd18-0.3-0.4-0.31.61.80.5
Lenalidomide and Low-Dose Dexamethasone (Rd)2.11.91.40.42.01.9
Melphalan + Prednisone + Thalidomide (MPT)0.51.90.71.10.45.0

Change From Baseline in the EORTC QLQ-C30 Insomnia Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd183.2-1.3-1.91.11.4-1.6
Lenalidomide and Low-Dose Dexamethasone (Rd)2.10.2-1.2-1.0-0.5-5.2
Melphalan + Prednisone + Thalidomide (MPT)-10.5-8.9-11.6-9.6-6.0-4.5

Change From Baseline in the EORTC QLQ-C30 Nausea/Vomiting Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea/Vomiting Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd18-0.5-2.5-4.0-3.6-2.7-4.2
Lenalidomide and Low-Dose Dexamethasone (Rd)1.8-1.1-1.3-2.2-2.30.4
Melphalan + Prednisone + Thalidomide (MPT)4.0-1.2-3.9-3.9-3.91.0

Change From Baseline in the EORTC QLQ-C30 Pain Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd18-4.4-13.1-16.1-14.7-12.4-7.9
Lenalidomide and Low-Dose Dexamethasone (Rd)-5.4-13.4-14.4-14.0-14.4-8.0
Melphalan + Prednisone + Thalidomide (MPT)-7.8-12.1-13.4-14.3-14.7-6.0

Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd18-1.44.77.67.46.83.0
Lenalidomide and Low-Dose Dexamethasone (Rd)-1.73.44.75.06.9-0.1
Melphalan + Prednisone + Thalidomide (MPT)-0.92.25.36.98.3-0.1

Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd18-4.66.38.69.49.13.8
Lenalidomide and Low-Dose Dexamethasone (Rd)-2.72.46.37.88.0-0.3
Melphalan + Prednisone + Thalidomide (MPT)-2.44.18.211.814.5-1.0

Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd18-2.22.05.23.83.22.7
Lenalidomide and Low-Dose Dexamethasone (Rd)-4.30.74.02.94.2-1.2
Melphalan + Prednisone + Thalidomide (MPT)-1.42.43.45.86.0-3.5

Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Study discontinuation
Lenalidomide and Dexamethasone Rd18-1.34.75.43.25.75.0
Lenalidomide and Low-Dose Dexamethasone (Rd)0.44.85.94.86.4-0.1
Melphalan + Prednisone + Thalidomide (MPT)1.04.36.16.54.80.3

Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Body Image Scale

EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the body image scale, a higher score indicates a better body image. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd18-1.50.81.5-0.4-0.31.8
Lenalidomide and Low-Dose Dexamethasone (Rd)-4.5-1.7-1.4-1.4-2.3-5.6
Melphalan + Prednisone + Thalidomide (MPT)-1.6-3.0-2.8-2.6-1.1-5.6

Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale

EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score indicates more severe disease symptom(s). (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd18-4.1-10.0-9.9-8.7-6.2-4.5
Lenalidomide and Low-Dose Dexamethasone (Rd)-4.0-9.1-8.8-7.8-8.7-3.5
Melphalan + Prednisone + Thalidomide (MPT)-4.4-7.0-7.9-6.5-7.9-3.7

Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale

EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the future perspective scale, a higher score indicates a better perspective of the future. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd183.99.212.312.111.78.8
Lenalidomide and Low-Dose Dexamethasone (Rd)4.78.59.810.812.75.8
Melphalan + Prednisone + Thalidomide (MPT)3.36.38.010.09.53.2

Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Side Effects Treatment Scale

EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score represents a more severe overall side effect of treatment. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd184.01.2-0.41.22.3-1.0
Lenalidomide and Low-Dose Dexamethasone (Rd)2.51.01.71.92.20.6
Melphalan + Prednisone + Thalidomide (MPT)5.63.52.94.74.33.8

Change From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Health Utility Index Score

EQ-5D is a self-administered questionnaire that assesses health-related quality of life. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where higher EQ-5D scores represent better health status. A positive change from baseline score indicates improvement in health status and better health state. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit

,,
Interventionunits on a scale (Mean)
Month 1Month 3Month 6Month 12Month 18Discontinuation Visit
Lenalidomide and Dexamethasone Rd18-0.00.10.10.10.10.0
Lenalidomide and Low-Dose Dexamethasone (Rd)0.00.10.10.10.10.0
Melphalan + Prednisone + Thalidomide (MPT)0.00.10.10.10.10.0

Number of Participants With Adverse Events (AEs) During the Active Treatment Phase

A TEAE is any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. (NCT00689936)
Timeframe: From first dose of study drug through 28 days following the discontinuation visit from active treatment phase; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

,,
InterventionParticipants (Number)
≥ 1 adverse event (AE)≥ 1 grade (Gr) 3 or 4 AE≥ 1 grade (Gr) 5 AE≥ 1 serious adverse event (SAE)≥ 1 AE related to Lenalidomide/Dex/Mel/Pred/Thal≥ 1 AE related to Lenalidomide≥ 1 AE related to dexamethasone≥ 1 AE related to melphalan≥ 1 AE related to prednisone≥ 1 AE related to thalidomide≥1 AE related to Lenalidomide/Dex or Mel/Pred/Thal≥ 1 Gr 3 or 4 AE related to Len/Dex/Mel/Pred/Thal≥ 1 grade 3 or 4 AE related to Lenalidomide≥ 1 grade 3 or 4 AE related to dexamethasone≥ 1 grade 3 or 4 AE related to melphalan≥ 1 grade 3 or 4 AE related to prednisone≥ 1 grade 3 or 4 AE related to Thalidomide≥1Gr 3 or 4 AE related to Len/Dex or Mel/Pred/Thal≥ 1 Grade 5 AE related to Len/Dex/Mel/Pred/Thal≥ 1 Grade 5 AE related to Lenalidomide≥ 1 Grade 5 AE related to Dexamethasone≥ 1 Grade 5 AE related to melphalan≥ 1 Grade 5 AE related to prednisone≥ 1 Grade 5 AE related to Thalidomide≥1 Grade 5 AE related to Len/Dex or Mel/Pred/Thal≥1 SAE related to Len/Dex/Mel/Pred/Thal≥1 SAE related to Lenalidomide≥1 SAE related to dexamethasone≥1 SAE related to melphalan≥1 SAE related to prednisone≥1 SAE related to thalidomide≥1 SAE related to Len/Dex or Mel/Pred/Thal≥1AE leading to Len/Dex/Mel/Pred/Thal Withdrawal≥1 AE leading to Lenalidomide withdrawal≥1 AE leading to dexamethasone withdrawal≥1 AE leading to melphalan withdrawal≥1 AE leading to prednisone withdrawal≥1 AE leading to Thalidomide withdrawal≥1AE leading to Len/DexOR Mel/Pred/Thal Withdrawal≥1AE leading to Len/Dex/Mel/Pred/Thal reduction≥1 AE leading to Lenalidomide reduction≥1 AE leading to dexamethasone reduction≥1 AE leading to melphalan reduction≥1 AE leading to prednisone reduction≥1 AE leading to thalidomide reduction≥1AE leading to Len/Dex or Mel/Pred/Thal reduction≥1 AE leading to Rd or MPT interruption≥1 AE leading to Lenalidomide interruption≥1 AE leading to dexamethasone interruption≥1 AE leading to melphalan interruption≥1 AE leading to prednisone interruption≥1 AE leading to Thalidomide interruption≥1 AE leading to Len and Dex or MPT interruption
Lenalidomide and Dexamethasone Rd1853643336308501481410000269326290177000104119700051581309700064109931040008421415511800020321301280000241
Lenalidomide and Low-Dose Dexamethasone (Rd)5294535035950648242900026937334222900013117121600011195165130000951571091520009627920317000030368353319000290
Melphalan + Prednisone + Thalidomide (MPT)53948038270527004413264931454230030711831649100065521420075629427153008378146713480019947254241900328324388249

Shift From Baseline to Most Extreme Postbaseline Value in Absolute Neutrophil Count During the Active Treatment Phase

Neutrophil counts was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

,,
Interventionparticipants (Number)
Normal Baseline Grade to Normal Postbaseline GradeNormal Baseline Grade to Grade 1 postbaselineNormal Baseline Grade to Grade 2 postbaselineNormal Baseline Grade to Grade 3 postbaselineNormal Baseline Grade to Grade 4 postbaselineGrade 1 Baseline to Normal postbaselineGrade1 Baseline to Grade 1 postbaselineGrade 1 Baseline to Grade 2 postbaselineGrade 1 Baseline to Grade 3 postbaselineGrade 1 Baseline to Grade 4 postbaselineGrade 2 Baseline to normal postbaselineGrade 2 Baseline to Grade 1 postbaselineGrade 2 Baseline to Grade 2 postbaselineGrade 2 Baseline to Grade 3 postbaselineGrade 2 Baseline to Grade 4 postbaselineGrade 3 Baseline to Normal postbaselineGrade 3 Baseline to Grade 1 postbaselineGrade 3 Baseline to Grade 2 postbaselineGrade 3 Baseline to Grade 3 postbaselineGrade3 Baseline to Grade 4 postbaselineGrade 4 Baseline to Normal postbaseline GradeGrade 4 Baseline to Grade 1 postbaseline GradeGrade 4 Baseline to Grade 2 postbaselineGrade 4 Baseline Grade to Grade 3 postbaselineGrade 4 Baseline to Grade 4 postbaseline
Lenalidomide and Dexamethasone Rd181338510971306111530401111850012200000
Lenalidomide and Low-Dose Dexamethasone (Rd)103961217021781725911141890022001000
Melphalan + Prednisone + Thalidomide (MPT)3779128141452211202101721100000100000

Shift From Baseline to Most Extreme Postbaseline Value in Creatinine Clearance (CrCl) During the Active Treatment Phase

Renal function was assessed for participants from baseline to the most extreme value in creatinine clearance calculated using the Cockcroft-Gault estimation. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

,,
Interventionparticipants (Number)
CrCl< 30 mL/min to CrCl< 30 mL/minCrCl < 30 mL/min to CrCl ≥ 30 but < 50 mL/minCrCl < 30 mL/min to CrCl ≥ 50 but < 80 mL/minCrCl< 30 mL/min to ≥ 80 mL/minCrCl≥ 30 but < 50 mL/min to < 30 mL/minCrCl ≥ 30 but < 50 mL/min to CrCl ≥ 30 but < 50 mLCrCl ≥ 30 but < 50 mL/min to CrCl ≥ 50 but < 80 mLCrCl ≥ 30 but < 50 mL/min to ≥ 80 mL/minCrCl ≥ 50 but < 80 mL to CrCl< 30 mL/minCrCl ≥ 50 but < 80 mL to CrCl ≥ 30 but < 50 mL/minCrCl ≥ 50 but < 80 mL to CrCl ≥ 50 but < 80 mL/minCrCl ≥ 50 but < 80 mL to ≥ 80 mL/minCrCl ≥ 80 mL/min to CrCl< 30 mL/minCrCl ≥ 80 mL/min to CrCl ≥ 30 but < 50 mL/minCrCl ≥ 80 mL/min to CrCl ≥ 50 but < 80 mL/minCrCl ≥ 80 mL/min to CrCl ≥ 80 mL/min
Lenalidomide and Dexamethasone Rd18171482241551201130991010114
Lenalidomide and Low-Dose Dexamethasone (Rd)15187213767904112107006109
Melphalan + Prednisone + Thalidomide (MPT)1919500416520410297009121

Shift From Baseline to Most Extreme Postbaseline Value in Hemoglobin During the Active Treatment Phase

Hemoglobin was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

,,
Interventionparticipants (Number)
Normal Baseline Grade to Normal Postbaseline GradeNormal Baseline Grade to Grade 1 postbaselineNormal Baseline Grade to Grade 2 postbaselineNormal Baseline Grade to Grade 3 postbaselineNormal Baseline Grade to Grade 4 postbaselineGrade 1 Baseline to Normal postbaselineGrade 1 Baseline to Grade 1 postbaselineGrade1 Baseline to Grade 2 postbaselineGrade 1 Baseline to Grade 3 postbaselineGrade 1 Baseline to Grade 4 postbaselineGrade 2 Baseline to normal postbaselineGrade 2 Baseline to Grade 1 postbaselineGrade 2 Baseline to Grade 2 postbaselineGrade 2 Baseline to Grade 3 postbaselineGrade 2 Baseline to Grade 4 postbaselineGrade 3 Baseline to Normal postbaselineGrade 3 Baseline to Grade 1 postbaselineGrade 3 Baseline to Grade 2 postbaselineGrade 3 Baseline to Grade 3 postbaselineGrade 3 Baseline to Grade 4 postbaselineGrade 4 Baseline to Normal postbaselineGrade 4 Baseline to Grade 1 postbaselineGrade 4 Baseline to Grade 2 postbaselineGrade 4 Baseline to Grade 3 postbaselineGrade 4 Baseline to Grade 4 postbaseline
Lenalidomide and Dexamethasone Rd18103081001261231750121354190148300011
Lenalidomide and Low-Dose Dexamethasone (Rd)639800010612825208125484001210500001
Melphalan + Prednisone + Thalidomide (MPT)92541001101232040141334711001010200102

Shift From Baseline to Most Extreme Postbaseline Value in Platelet Count During the Active Treatment Phase.

Improvement in platelets was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm

,,
Interventionparticipants (Number)
Normal Baseline Grade to Normal Postbaseline GradeNormal Baseline Grade to Grade 1 postbaselineNormal Baseline Grade to Grade 2 postbaselineNormal Baseline Grade to Grade 3 postbaselineNormal Baseline Grade to Grade 4 postbaselineGrade1 Baseline to Normal postbaseline GradeGrade 1 Baseline to Grade 1 postbaselineGrade 1 Baseline to Grade 2 postbaselineGrade 1 Baseline to Grade 3 postbaselineGrade 1 Baseline to Grade 4 postbaselineGrade 2 Baseline to normal postbaseline GradeGrade 2 Baseline to Grade 1 postbaselineGrade 2 Baseline to Grade 2 postbaselineGrade 2 Baseline to Grade 3 postbaselineGrade 2 Baseline to Grade 4 postbaselineGrade 3 Baseline to Normal postbaseline GradeGrade 3 Baseline to Grade 1 postbaselineGrade 3 Baseline to Grade 2 postbaselineGrade 3 Baseline to Grade 3 postbaselineGrade 3 Baseline to Grade 4 postbaseline
Lenalidomide and Dexamethasone Rd1819721130125338191210132000001
Lenalidomide and Low-Dose Dexamethasone (Rd)19721624154134151020033100002
Melphalan + Prednisone + Thalidomide (MPT)16520827311165171010212200110

Number of Patients With Objective Response (Complete and Partial Response + Hematological Improvement)

Time to response defined as the time from start of therapy until the response criteria are fulfilled. Response duration defined as the time from response until relapse (progressive disease) or death. (NCT00352794)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Lenalidomide + Prednisone14

Number of Participants With Complete Response and Partial Response

Complete response is transfusion independence with hemoglobin >9 gm/dl; partial response is transfusion dependence with hemoglobin < 9gm/dl with an increase in reticulocyte count over baseline (NCT01464164)
Timeframe: 9 months

InterventionParticipants (Count of Participants)
Sotatercept Cohort 10
Sotatercept Cohort 20
Sotatercept Cohort 30
Sotatercept With Prednisone Boost Cohort 4a0
Sotatercept Cohort 4b0
Sotatercept With Prednisone Boost Cohort 5a0
Sotatercept Cohort 5b0

Severe Adverse Events Attributable to Study Drug

Assess severity of adverse events and relationship to sotatercept according to the currently active minor version of the NCI Common Terminology for Adverse Events version 4.0 (NCT01464164)
Timeframe: 9 months

InterventionParticipants (Count of Participants)
Sotatercept Cohort 10
Sotatercept Cohort 20
Sotatercept Cohort 30
Sotatercept With Prednisone Boost Cohort 4a0
Sotatercept Cohort 4b0
Sotatercept With Prednisone Boost Cohort 5a0
Sotatercept Cohort 5b0

Toxicity of Participants Receiving Bortezomib, Rituximab, Cyclophosphamide, and Prednisone for Treatment of Non-Hodgkin's Lymphoma

Toxicity assessed using NCI-CTC v. 3.0 (NCT00295932)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide4
1.6 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamide6
1.6 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide3
1.8 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphamide4
Dose Level 1- 1.0 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid2
Dose Level 2 - 1.3 mg/m2 Bortezomib; 750 mg/m2 Cyclophosphamid18
Dose Level 3 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophospham3
Dose Level 4 - 1.5 mg/m2 Bortezomib; 1000 mg/m2 Cyclophosphami4
Dose Level 5 - 1.3 mg/m2 Bortezomib; 1000 mg/m2 Cyclophospham10
Weekly Bortezomib Dosing Schedule12
Twice-weekly Bortezomib Dosing Schedule13

Maximum Tolerated Dose

Maximum tolerated dose of Bortezomib in combination with Rituximab, Cyclophosphamide and Prednisone in Phase I participants (NCT00295932)
Timeframe: 2 years

Interventionmg/m^2 of Bortezomib (Number)
Weekly BortezomibTwice-Weekly Bortezomib
Arm I1.81.5

Complete Response

Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles

InterventionPercentage of Participants (Number)
FCR With Lenalidomide45

Overall Response Rate

Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles

InterventionPercentage of Participants (Number)
FCR With Lenalidomide95

Reviews

20 reviews available for prednisone and Anemia

ArticleYear
Celiac disease and idiopathic pulmonary hemosiderosis: a literature review of the Lane-Hamilton syndrome.
    Postgraduate medicine, 2022, Volume: 134, Issue:8

    Topics: Adult; Anemia; Celiac Disease; Child; Hemoptysis; Hemosiderosis; Hemosiderosis, Pulmonary; Humans; L

2022
Persistent Mild Anemia and Hypercalcemia were Ignored as Normal Reaction Secondary to Oral Calcium Supplementation in a Steroid-Dependent Asthma Patient Ultimately Diagnosed as Multiple Myeloma: a Case Report and Literature Review.
    Clinical laboratory, 2019, May-01, Volume: 65, Issue:5

    Topics: Aged; Anemia; Asthma; Calcium; Diagnosis, Differential; Dietary Supplements; Glucocorticoids; Humans

2019
Pregnancy in renal transplant recipients.
    Advances in chronic kidney disease, 2013, Volume: 20, Issue:3

    Topics: Anemia; Azathioprine; Cyclosporine; Cytomegalovirus Infections; Female; Herpes Simplex; Humans; Immu

2013
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
    Vnitrni lekarstvi, 2016, Volume: 62, Issue:1

    Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoc

2016
Postpartum-acquired haemophilia A: a description of three cases and literature review.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:6

    Topics: Adult; Anemia; Autoantibodies; Autoimmune Diseases; Blood Transfusion; Combined Modality Therapy; Cu

2009
Primary effusion anaplastic large cell lymphoma in a patient with long-standing dermatitis herpetiformis and celiac disease.
    Annals of hematology, 2013, Volume: 92, Issue:2

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Celiac Disease; Cyclophosphamide; Derm

2013
B19 virus infection in renal transplant recipients.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2003, Volume: 26, Issue:3

    Topics: Anemia; Antibodies, Monoclonal; Antibodies, Viral; Antilymphocyte Serum; Basiliximab; Cyclosporine;

2003
[Retroperitoneal fibrosis, an unrecognized inflammatory disease. Clinical observations and review of the literature].
    Nephrologie, 2003, Volume: 24, Issue:4

    Topics: Aged; Anemia; Aortic Aneurysm; Female; Humans; Inflammation; Male; Middle Aged; Pain; Prednisone; Pr

2003
[APLASTIC ANEMIA IN CHILDREN AND ITS THERAPY].
    [Chiryo] [Therapy], 1964, Volume: 46

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anemia; Anemia, Aplastic; Child; D

1964
Successful combination of antifungal agents and surgical resection for pulmonary aspergillosis in a child with Hodgkin disease: review of the literature.
    Pediatric hematology and oncology, 2007, Volume: 24, Issue:8

    Topics: Adolescent; Amphotericin B; Anemia; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocol

2007
Temporal arteritis: a review and case history.
    The Journal of family practice, 1996, Volume: 43, Issue:3

    Topics: Aged; Anemia; Blood Sedimentation; Female; Giant Cell Arteritis; Humans; Prednisone

1996
Inflammatory bowel disease and immune thrombocytopenic purpura: is there a correlation?
    The American journal of gastroenterology, 1997, Volume: 92, Issue:12

    Topics: Adolescent; Adult; Anemia; Anti-Inflammatory Agents; Colitis, Ulcerative; Crohn Disease; Female; Hum

1997
Treatment of multiple myeloma.
    Haematologica, 1999, Volume: 84, Issue:1

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplanta

1999
[Adult Still's disease: study of a series of 11 cases].
    Journal des maladies vasculaires, 2002, Volume: 27, Issue:1

    Topics: Adult; Anemia; Diagnosis, Differential; Exanthema; Female; Ferritins; Fever; Humans; Incidence; Infe

2002
Diagnosis and management of multiple myeloma and related disorders.
    Progress in hematology, 1986, Volume: 14

    Topics: Alkylating Agents; Amyloidosis; Anemia; Anemia, Refractory; Animals; Antibodies, Monoclonal; Antineo

1986
Multiple myeloma: current therapy and a glimpse of the future.
    Scandinavian journal of haematology, 1985, Volume: 35, Issue:1

    Topics: Acute Kidney Injury; Anemia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols;

1985
Exofoliative dermatitis (erythroderma).
    Current problems in dermatology, 1972, Volume: 4

    Topics: Adrenal Cortex Hormones; Adult; Anemia; Blood Proteins; Body Temperature Regulation; Cardiac Output;

1972
Steroid therapy of multiple myeloma and macroglobulinemia.
    The Medical clinics of North America, 1973, Volume: 57, Issue:5

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anemia; Anemia, Hemolytic, Autoimmune; Blood U

1973
[Current therapeutic possibilities in idiopathic myelofibrosis. Observations on 47 cases].
    La Clinica terapeutica, 1968, Apr-15, Volume: 45, Issue:1

    Topics: Adrenal Cortex Hormones; Adult; Androgens; Anemia; Busulfan; Drug Synergism; Female; Humans; Leukocy

1968
The treatment of chronic lymphocytic leukemia.
    Seminars in hematology, 1969, Volume: 6, Issue:4

    Topics: Adrenal Cortex Hormones; Alkylating Agents; Anemia; Anemia, Hemolytic, Autoimmune; Anti-Bacterial Ag

1969

Trials

29 trials available for prednisone and Anemia

ArticleYear
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
    Haematologica, 2017, Volume: 102, Issue:12

    Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide;

2017
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
    Haematologica, 2017, Volume: 102, Issue:12

    Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide;

2017
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
    Haematologica, 2017, Volume: 102, Issue:12

    Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide;

2017
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
    Haematologica, 2017, Volume: 102, Issue:12

    Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide;

2017
Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.
    Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:4

    Topics: Administration, Oral; Aged; Anemia; Dose-Response Relationship, Drug; Drug Administration Schedule;

2019
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Jan-10, Volume: 32, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Di

2014
Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:2

    Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoco

2014
Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
    Clinical therapeutics, 2014, Apr-01, Volume: 36, Issue:4

    Topics: Anemia; Bayes Theorem; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Myeloproliferativ

2014
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
    Leukemia research, 2014, Volume: 38, Issue:9

    Topics: Aged; Aged, 80 and over; Anemia; Drug Administration Schedule; Drug Therapy, Combination; Female; Hu

2014
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study.
    Clinical advances in hematology & oncology : H&O, 2016, Volume: 14, Issue:2 Suppl 1

    Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosp

2016
Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia.
    Transfusion, 2016, Volume: 56, Issue:10

    Topics: Anemia; Blood Group Antigens; Female; Hemoglobins; Humans; Immunoglobulins, Intravenous; Mothers; Pr

2016
Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial.
    International journal of radiation oncology, biology, physics, 2016, 12-01, Volume: 96, Issue:5

    Topics: Adolescent; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Prescho

2016
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
    British journal of haematology, 2017, Volume: 176, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap

2017
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
    British journal of haematology, 2017, Volume: 176, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap

2017
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
    British journal of haematology, 2017, Volume: 176, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap

2017
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
    British journal of haematology, 2017, Volume: 176, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap

2017
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-20, Volume: 27, Issue:27

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Double-Blind Method; Female; Glucocorticoids; Hematinics; Hu

2009
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-01, Volume: 27, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Therapy, Combination; Enzyme-Lin

2009
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy P

2009
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-01, Volume: 28, Issue:13

    Topics: Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphami

2010
Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer.
    Hematology/oncology and stem cell therapy, 2010, Volume: 3, Issue:3

    Topics: Aged; Alopecia; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoc

2010
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8

    Topics: Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boro

2011
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINT
    Leukemia & lymphoma, 2012, Volume: 53, Issue:4

    Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Che

2012
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:3

    Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Bleomycin; Carbopl

2012
Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma.
    The oncologist, 2012, Volume: 17, Issue:6

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived;

2012
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
    Blood, 2003, Apr-01, Volume: 101, Issue:7

    Topics: Adrenal Cortex Hormones; Aged; Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Ant

2003
14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-01, Volume: 21, Issue:9

    Topics: Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphami

2003
Vindesine, prednisone, and daunomycin in acute lymphoblastic leukemia in relapse.
    Cancer chemotherapy and pharmacology, 1983, Volume: 10, Issue:3

    Topics: Adolescent; Adult; Anemia; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic;

1983
OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma.
    Leukemia & lymphoma, 2000, Volume: 40, Issue:1-2

    Topics: Adult; Aged; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cau

2000
Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin's lymphoma in elderly patients: a prospective study.
    Annals of hematology, 2001, Volume: 80, Issue:10

    Topics: Aged; Aging; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami

2001
Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia.
    Blood, 1977, Volume: 50, Issue:6

    Topics: Anemia; Chlorambucil; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administratio

1977
Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia.
    Blood, 1977, Volume: 50, Issue:6

    Topics: Anemia; Chlorambucil; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administratio

1977
Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia.
    Blood, 1977, Volume: 50, Issue:6

    Topics: Anemia; Chlorambucil; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administratio

1977
Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia.
    Blood, 1977, Volume: 50, Issue:6

    Topics: Anemia; Chlorambucil; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administratio

1977
Prognostic factors in multiple myeloma.
    Cancer, 1975, Volume: 36, Issue:4

    Topics: Aged; Anemia; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Immunoglobulins; Male; Melph

1975
Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone.
    Cancer, 1985, Nov-15, Volume: 56, Issue:10

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials as Topic

1985
Bites by the saw-scaled or carpet viper (Echis carinatus): trial of two specific antivenoms.
    British medical journal, 1974, Nov-23, Volume: 4, Issue:5942

    Topics: Acute Disease; Anemia; Antivenins; Blood Coagulation; Cerebral Hemorrhage; Codeine; Epinephrine; Fib

1974
Chemotherapy of acute leukemia. Comparison of cytarabine alone and in combination with vincristine, prednisone, and cyclophosphamide.
    Archives of internal medicine, 1974, Volume: 133, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Anemia; Chemical and Drug Induced Liver Injury;

1974

Other Studies

204 other studies available for prednisone and Anemia

ArticleYear
Eosinophilic Gastroenteritis: Using Presenting Findings to Predict Disease Course.
    Clinical and translational gastroenterology, 2021, 10-08, Volume: 12, Issue:10

    Topics: Adult; Anemia; Anti-Inflammatory Agents; Budesonide; Chronic Disease; Enteritis; Eosinophilia; Femal

2021
Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study.
    Hematological oncology, 2022, Volume: 40, Issue:4

    Topics: Anemia; Danazol; Hemoglobins; Humans; Myeloproliferative Disorders; Nitriles; Pilot Projects; Predni

2022
[The 475th case: renal tubular acidosis, renal failure, anemia, and lactic acidosis].
    Zhonghua nei ke za zhi, 2020, Feb-01, Volume: 59, Issue:2

    Topics: Acidosis, Lactic; Acidosis, Renal Tubular; Anemia; Antineoplastic Agents; Biopsy; Creatinine; Erythr

2020
Outcomes of treatment with CHOP and EPOCH in patients with HIV associated NHL in a low resource setting.
    BMC cancer, 2020, Aug-24, Volume: 20, Issue:1

    Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug A

2020
Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era.
    Platelets, 2019, Volume: 30, Issue:5

    Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Che

2019
Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy.
    Oncology research, 2019, Mar-29, Volume: 27, Issue:4

    Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Pr

2019
Risk factors for development of early infectious and noninfectious complications in systemic lupus erythematosus patients undergoing major surgery.
    Lupus, 2018, Volume: 27, Issue:12

    Topics: Adolescent; Adult; Aged; Anemia; Aspirin; Child; Elective Surgical Procedures; Female; Humans; Logis

2018
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
    BMC cancer, 2019, Aug-05, Volume: 19, Issue:1

    Topics: Abiraterone Acetate; Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Ag

2019
Disseminated histoplasmosis: a cause of hemophagocytic syndrome.
    Mayo Clinic proceedings, 2013, Volume: 88, Issue:10

    Topics: Adult; Anemia; Anti-Bacterial Agents; Anti-Inflammatory Agents; Asthma; Bone Marrow Cells; Erythroid

2013
Systemic mastocytosis accompanied by a non-secretory plasma cell dyscrasia and nephrotic syndrome-level proteinuria in a 76-year-old patient.
    Acta haematologica, 2014, Volume: 131, Issue:2

    Topics: Aged; Amyloidosis; Anemia; Biopsy; Bone Marrow; Clone Cells; Coloring Agents; Congo Red; Darbepoetin

2014
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:6

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use T

2014
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Proto

2014
[Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:8

    Topics: Adult; Aged; Anemia; Danazol; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mi

2014
An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort.
    Rheumatology (Oxford, England), 2015, Volume: 54, Issue:4

    Topics: Adult; Anemia; Black or African American; Cohort Studies; Cost-Benefit Analysis; Female; Health Care

2015
Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.
    Cancer science, 2014, Volume: 105, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combi

2014
Long-term results of prednisone treatment for the anemia of myelofibrosis.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:1

    Topics: Aged; Anemia; Anti-Inflammatory Agents; Bone Marrow; Erythrocyte Indices; Female; Humans; Immunosupp

2016
[Systemic lupus erythematosus presenting as Stevens-Johnson syndrome].
    Pathologie-biologie, 2015, Volume: 63, Issue:4-5

    Topics: Adult; Anemia; Arthralgia; Autoantibodies; Complement C3; Critical Care; Facial Dermatoses; Female;

2015
Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combi

2015
Severe Alveolar Hemorrhage - What's in it for the Gastroenterologist?
    Journal of gastrointestinal and liver diseases : JGLD, 2016, Volume: 25, Issue:4

    Topics: Anemia; Biopsy; Celiac Disease; Diet, Gluten-Free; Endoscopy, Gastrointestinal; Female; Glucocortico

2016
[Autoimmune disorder secondary to DiGeorge syndrome: a long-term follow-up case report and literature review].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2016, 12-18, Volume: 48, Issue:6

    Topics: Anemia; Autoimmune Diseases; Cleft Palate; Cyclophosphamide; DiGeorge Syndrome; Face; Female; Follow

2016
Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) occurring in association with nodal marginal zone lymphoma: a case report.
    Dermatology online journal, 2008, Aug-15, Volume: 14, Issue:8

    Topics: Acitretin; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co

2008
A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients.
    Transplantation proceedings, 2009, Volume: 41, Issue:8

    Topics: Analysis of Variance; Anemia; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Cholesterol; C

2009
Anti-epoetin-antibody-induced anemia in a child with chronic renal failure.
    Pediatric nephrology (Berlin, Germany), 2010, Volume: 25, Issue:5

    Topics: Anemia; Antibodies; Child, Preschool; Cyclosporine; Drug Therapy, Combination; Erythropoietin; Hemat

2010
Polyarthritis and anemia in a hemodialysis patient: systemic lupus erythematosus following treatment with interferon alpha.
    Clinical nephrology, 2010, Volume: 73, Issue:4

    Topics: Adult; Anemia; Antiviral Agents; Arthritis; Glucocorticoids; Hepatitis C, Chronic; Humans; Interfero

2010
Eruptive neutrophilic xanthomas.
    Dermatology online journal, 2010, Apr-15, Volume: 16, Issue:4

    Topics: Acyclovir; Anemia; Clobetasol; Colchicine; Dermatitis; Humans; Male; Middle Aged; Neutrophils; Predn

2010
Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
    Journal of the National Cancer Institute, 2010, Jun-16, Volume: 102, Issue:12

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Ble

2010
Diamond-Blackfan anemia, ribosome and erythropoiesis.
    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2010, Volume: 17, Issue:3

    Topics: Anemia; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Blood Transfusion; Bone Marrow; Chromosomes, H

2010
[Acquired ichthyosis and haematological malignancies: five cases].
    Annales de dermatologie et de venereologie, 2012, Volume: 139, Issue:1

    Topics: Adult; Aged; Allopurinol; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Ant

2012
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine

2012
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.
    European urology, 2013, Volume: 63, Issue:6

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use T

2013
Prenatal suspicion of Kaposiform hemangioendo-thelioma in siblings: different clinical manifestation and emergency relief.
    Klinische Padiatrie, 2012, Volume: 224, Issue:6

    Topics: Anemia; Anti-Inflammatory Agents; Blood Transfusion, Intrauterine; Cesarean Section; Diagnosis, Diff

2012
Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral T-cell lymphomas.
    Oncology reports, 2013, Volume: 29, Issue:2

    Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality T

2013
Anemia of cancer in intermediate-grade non-Hodgkin's lymphoma.
    Southern medical journal, 2002, Volume: 95, Issue:8

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Community Health Services; Cyclophosph

2002
[Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].
    Annales de medecine interne, 2003, Volume: 154, Issue:3

    Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem

2003
Prednisone (meticorten) in treatment of acquired hemolytic anemia; preliminary report.
    Journal of the American Medical Association, 1956, Jan-28, Volume: 160, Issue:4

    Topics: Anemia; Anemia, Hemolytic; Humans; Prednisone; Steroids; Tracheophyta

1956
[Prednisone and hemopathy].
    Minerva medica, 1955, Dec-12, Volume: 46, Issue:99

    Topics: Anemia; Anemia, Hemolytic; Hodgkin Disease; Humans; Leukemia; Prednisone; Steroids

1955
Use of prednisone in the management of some hemorrhagic states.
    The New England journal of medicine, 1956, Feb-16, Volume: 254, Issue:7

    Topics: Anemia; Anemia, Aplastic; Hemophilia A; Humans; Leukemia; Prednisone; Purpura; Purpura, Thrombocytop

1956
[Prednisone therapy of acquired hemolytic anemia].
    Arztliche Wochenschrift, 1957, Jun-07, Volume: 12, Issue:23-24

    Topics: Anemia; Anemia, Hemolytic; Humans; Prednisone; Tracheophyta

1957
[Prednisone therapy of chronic erythroblastophthisis].
    Archiv fur Kinderheilkunde, 1957, Volume: 155, Issue:3

    Topics: Anemia; Anemia, Aplastic; Child; Humans; Infant; Prednisone

1957
Treatment of symptomatic hemolytic anemia with prednisone.
    The New England journal of medicine, 1957, Oct-03, Volume: 257, Issue:14

    Topics: Anemia; Anemia, Hemolytic; Humans; Prednisone

1957
[Physiopathological findings on 2 cases of Cooley's anemia (talasanemia major) treated with prednisone].
    Prensa medica argentina, 1957, Apr-12, Volume: 44, Issue:15

    Topics: Anemia; beta-Thalassemia; Erythroblasts; Humans; Prednisone; Tracheophyta

1957
[Hemolytic anemia caused by autoantibodies treated with prednisone and splenectomy].
    Il Policlinico. Sezione pratica, 1957, Jul-29, Volume: 64, Issue:30

    Topics: Anemia; Anemia, Hemolytic; Autoantibodies; Humans; Prednisone; Spleen; Splenectomy; Tracheophyta

1957
Acquired haemolytic anaemia.
    Journal of the Indian Medical Association, 1957, Nov-16, Volume: 29, Issue:10

    Topics: Anemia; Anemia, Hemolytic; Child; Humans; Infant; Prednisone

1957
[Prednisone treatment of auto-immune hemolytic anemia].
    La Riforma medica, 1957, Dec-28, Volume: 71, Issue:52

    Topics: Anemia; Anemia, Hemolytic; Prednisone; Tracheophyta

1957
Acquired haemolytic anemia (clinical case).
    Strasbourg medical, 1957, Volume: 8, Issue:11

    Topics: Anemia; Anemia, Hemolytic; Humans; Prednisone; Tracheophyta

1957
Observations on vitamin B12 absorption in primary pernicious anemia during administration of adrenocortical steroids.
    The New England journal of medicine, 1958, May-29, Volume: 258, Issue:22

    Topics: Anemia; Anemia, Pernicious; Humans; Prednisone; Vitamin B 12

1958
Effect of prednisolone on anaemia associated with macroglobulinemia.
    British medical journal, 1958, Dec-20, Volume: 2, Issue:5111

    Topics: Anemia; Globulins; Humans; Prednisolone; Prednisone; Serum Globulins; Waldenstrom Macroglobulinemia

1958
Red-cell aplasia and benign thymoma; studies on a case responding to prednisone.
    British medical journal, 1959, May-02, Volume: 1, Issue:5130

    Topics: Anemia; Anemia, Aplastic; Humans; Prednisone; Red-Cell Aplasia, Pure; Thymoma

1959
The mechanism of the prednisone effect upon B12 absorption in pernicious anaemia.
    Acta medica Scandinavica, 1960, Dec-20, Volume: 168

    Topics: Anemia; Anemia, Pernicious; Biochemical Phenomena; Humans; Prednisone; Tracheophyta; Vitamin B 12

1960
[Mechanism of the prednisone effect on vitamin B12 absorption in pernicious anemia].
    Ugeskrift for laeger, 1960, Sep-23, Volume: 122

    Topics: Anemia; Anemia, Pernicious; Humans; Prednisone; Vitamin B 12

1960
[Associated androgen therapy and corticotherapy (Shahidi-Diamond method) in Fanconi's anemia].
    Pediatrie, 1960, Volume: 15

    Topics: Anemia; Anemia, Aplastic; Diamond; Fanconi Anemia; Hormone Replacement Therapy; Humans; Prednisone;

1960
[Total remission after prednisone and tetracycline therapy in a case of megaloblastic anemia resistant to liver extracts and vitamin B12].
    Minerva medica, 1959, Sep-26, Volume: 50

    Topics: Anemia; Anemia, Megaloblastic; Anti-Bacterial Agents; Humans; Liver Extracts; Prednisone; Tetracycli

1959
[Treatment of some infantile hemopathies with prednisone and prednisolone].
    Minerva pediatrica, 1959, Dec-15, Volume: 11

    Topics: Anemia; beta-Thalassemia; Child; Humans; Infant; Leukemia; Prednisolone; Prednisone

1959
[Acquired hemolytic anemia: clinical course and evaluation of the effectiveness of prednisone therapy in a case followed-up for 4 years].
    Haematologica, 1961, Volume: 46

    Topics: Anemia; Anemia, Hemolytic; Prednisone

1961
Aplastic anemia treated with anabolic steroids and corticosteroids.
    Acta paediatrica, 1961, Volume: 50

    Topics: Anemia; Anemia, Aplastic; Glucocorticoids; Humans; Prednisone; Steroids; Testosterone Congeners

1961
Remission of hypoplastic anemia in an adult following combined androgen and corticosteroid therapy.
    Quarterly bulletin. Northwestern University (Evanston, Ill.). Medical School, 1962, Volume: 36

    Topics: Adrenal Cortex Hormones; Adult; Anatomy; Androgens; Anemia; Anemia, Aplastic; Fluoxymesterone; Human

1962
[Drug treatment of acquired hemolytic anemia].
    Nordisk medicin, 1963, Jul-04, Volume: 70

    Topics: Adrenocorticotropic Hormone; Anemia; Anemia, Hemolytic; Blood Transfusion; Humans; Mercaptopurine; P

1963
Current concepts in therapy. Hemolytic anemia.
    The New England journal of medicine, 1963, Feb-28, Volume: 268

    Topics: Adrenocorticotropic Hormone; Anemia; Anemia, Hemolytic; Chelating Agents; Cortisone; Erythropoiesis;

1963
Autoimmune hemolytic anemia in a 6-week-old child.
    The Journal of pediatrics, 1962, Volume: 61

    Topics: Adrenocorticotropic Hormone; Anemia; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Autoimmune Di

1962
Reactivation of pulmonary tuberculosis following steroid therapy for aplastic anemia.
    American practitioner and digest of treatment, 1962, Volume: 13

    Topics: Anemia; Anemia, Aplastic; Humans; Prednisone; Tuberculosis; Tuberculosis, Pulmonary

1962
FAMILIAL VITAMIN B12 MALABSORPTION.
    Acta haematologica, 1963, Volume: 30

    Topics: Anemia; Anemia, Macrocytic; Child; Cobalt Isotopes; Genetics, Medical; Hematinics; Humans; Infant; M

1963
[OBSERVATIONS ON THE USE OF TESTOSTERONE IN APLASTIC ANEMIA IN ADULT SUBJECTS].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1963, Jun-17, Volume: 18

    Topics: Adult; Anemia; Anemia, Aplastic; Humans; Prednisone; Testosterone

1963
CONGENITAL HYPOPLASTIC ANAEMIA: A CASE REPORT.
    The Journal of the Association of Physicians of India, 1963, Volume: 11

    Topics: Anemia; Anemia, Aplastic; Anemia, Hypoplastic, Congenital; Genetics, Medical; Hemoglobinometry; Huma

1963
CYCLIC HAEMOLYTIC ANAEMIA SYNCHRONOUS WITH PEL-EBSTEIN FEVER IN A CASE OF HODGKIN'S DISEASE.
    Acta medica Scandinavica, 1963, Volume: 174

    Topics: Anemia; Anemia, Hemolytic; Antineoplastic Agents; Blood Transfusion; Bronchopneumonia; Fever; Hodgki

1963
[IDIOPATHIC PULMONARY HEMOSIDEROSIS].
    Revista chilena de pediatria, 1963, Volume: 34

    Topics: Anemia; Biopsy; Child; Hemosiderosis; Hemosiderosis, Pulmonary; Humans; Infant; Lung Diseases; Predn

1963
CONGENITAL CYSTS OF THE RENAL MEDULLA. A CASE WITH SEVERE REFRACTORY ANEMIA.
    American journal of diseases of children (1960), 1964, Volume: 107

    Topics: Adolescent; Anemia; Anemia, Aplastic; Anemia, Refractory; Biopsy; Bone Marrow Examination; Child; Cy

1964
[ON HYPERGLOBULINEMIC PURPURA AND ACQUIRED HEMOLYTIC ANEMIA IN THE SAME PATIENT].
    Schweizerische medizinische Wochenschrift, 1963, Oct-26, Volume: 93

    Topics: Anemia; Anemia, Hemolytic; Humans; Prednisone; Purpura; Purpura, Hyperglobulinemic; Tuberculosis

1963
EFFECT OF CORTICOSTEROID THERAPY ON FIBRINOLYSIS IN PATIENTS WITH INFLAMMATORY AND NON-INFLAMMATORY CONDITIONS.
    British medical journal, 1964, Feb-29, Volume: 1, Issue:5382

    Topics: Addison Disease; Adenoma; Adenoma, Chromophobe; Adrenocorticotropic Hormone; Anemia; Anemia, Aplasti

1964
APLASTIC ANEMIA IN PREGNANCY: REPORT OF A CASE.
    Obstetrics and gynecology, 1964, Volume: 23

    Topics: Anemia; Anemia, Aplastic; Blood Cell Count; Bone Marrow Examination; Colistin; Erythromycin; Female;

1964
[BENZENE BLOOD DISEASE. 3 CASES OF CHRONIC BENZENE POISONING OF WHICH 2 WERE FATAL (ACUTE LEUKEMIA, ACUTE PANMYELOPHTHISIS)].
    La Medicina del lavoro, 1963, Volume: 54

    Topics: Adrenocorticotropic Hormone; Anemia; Anemia, Myelophthisic; Anti-Bacterial Agents; Ascorbic Acid; Be

1963
THROMBOEMBOLIC PHENOMENA IN ULCERATIVE COLITIS. TWO CASE REPORTS.
    Archives of internal medicine, 1964, Volume: 113

    Topics: Anemia; Anemia, Hemolytic; Autoimmune Diseases; Blood Coagulation; Chlordiazepoxide; Colitis; Coliti

1964
[PULMONARY IDIOPATHIC HEMOSIDEROSIS, LITTLE KNOWN ETIOLOGY OF CHRONIC POSTHEMORRHAGIC ANEMIA].
    Medicina clinica, 1963, Volume: 41

    Topics: Anemia; Anemia, Hypochromic; Anemia, Sideroblastic; Bone Marrow Examination; Child; Cytodiagnosis; G

1963
[CONGENITAL HYPOPLASTIC STATE OF THE HEMATOPOIETIC SYSTEM IN CHILDREN].
    Pediatriia, 1963, Volume: 42

    Topics: Anemia; Anemia, Aplastic; Ascorbic Acid; Bilirubin; Blood Cell Count; Blood Chemical Analysis; Blood

1963
[CASE OF SEVERE HYPERAZOTEMIC HEMOLYTIC JAUNDICE WITH FAVORABLE DEVELOPMENT IN A NEWBORN CHILD].
    Minerva pediatrica, 1963, Dec-15, Volume: 15

    Topics: Anemia; Anemia, Hemolytic; Blood Transfusion; Child; Erythrocytes; Humans; Infant; Infant, Newborn;

1963
APLASTIC ANAEMIA TREATED BY TRANSPLANTATION OF ISOLOGOUS BONE MARROW.
    The New Zealand medical journal, 1964, Volume: 63

    Topics: Anabolic Agents; Anemia; Anemia, Aplastic; Bone Marrow; Bone Marrow Transplantation; Bronchitis; Chl

1964
WEEKLY HIGH-DOSAGE GLUCOCORTICOSTEROID TREATMENT OF LYMPHOCYTIC LEUKEMIAS AND LYMPHOMAS.
    The New England journal of medicine, 1964, May-28, Volume: 270

    Topics: Anemia; Anemia, Hemolytic; Betamethasone; Chlorambucil; Dexamethasone; Geriatrics; Humans; Leukemia;

1964
[PROBLEM OF DIAGNOSIS AND THERAPY IN THROMBOTIC THROMBOCYTOPENIC PURPURA (MOSCOWITZ'S SYNDROME)].
    Annales paediatrici. International review of pediatrics, 1964, Volume: 202

    Topics: Anemia; Anemia, Hemolytic; Autopsy; Child; Cortisone; Electrocardiography; Epistaxis; Hematemesis; H

1964
[MICROANEURYSMS OF THE VASCULAR FIELD OF THE BULBAR CONJUNCTIVA IN INTERNAL PATHOLOGY. BIOMICROSCOPIC STUDY].
    Annales d'oculistique, 1964, Volume: 197

    Topics: Anemia; Anemia, Sickle Cell; Aneurysm; Arteriosclerosis; Conjunctiva; Diabetic Angiopathies; Eye Man

1964
[PANMYELPHTHISIS AND ANTI-CHLOROMYCETIN ANTIBODIES].
    Archives francaises de pediatrie, 1964, Volume: 21

    Topics: Anemia; Anemia, Aplastic; Cerebral Hemorrhage; Child; Chloramphenicol; Drug Hypersensitivity; Predni

1964
[CONGENITAL HYPOPLASTIC ERYTHROID ANEMIA IN INFANTS].
    Ceskoslovenska pediatrie, 1964, Volume: 19

    Topics: Anemia; Anemia, Diamond-Blackfan; Blood Transfusion; Hematopoietic System; Humans; Infant; Prednison

1964
[COMPARATIVE PROGNOSTIC VALUE OF STERNAL PUNCTURE AND MEDULLARY BIOPSY IN THE CLINICAL AND HEMATOLOGICAL STUDY OF 52 CASES OF MEDULLARY INSUFFICIENCY].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1964, May-14, Volume: 40

    Topics: Anemia; Anemia, Aplastic; Biopsy; Bone Marrow; Bone Marrow Examination; Diagnosis; Humans; Pathology

1964
BONE-MARROW TRANSPLANT IN AN IDENTICAL TWIN.
    JAMA, 1964, Jun-22, Volume: 188

    Topics: Allergy and Immunology; Anabolic Agents; Anemia; Anemia, Aplastic; Blood Transfusion; Bone Marrow; B

1964
PRESENT-DAY MANAGEMENT OF RHEUMATOID ARTHRITIS.
    GP, 1964, Volume: 30

    Topics: Anemia; Arthritis; Arthritis, Rheumatoid; Climate; Diet; Diet Therapy; Exercise Therapy; Gold; Hot T

1964
[AUTOIMMUNE HEMOLYTIC ANEMIA IN AN INFANT].
    Rivista di clinica pediatrica, 1963, Volume: 72

    Topics: Adrenocorticotropic Hormone; Anemia; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Autoimmune Di

1963
CASE HISTORIES FROM THE STAFF CONFERENCES OF THE SLOANE HOSPITAL.
    Bulletin of the Sloane Hospital for Women in the Columbia-Presbyterian Medical Center, New York City, 1964, Volume: 10

    Topics: Accidents; Accidents, Occupational; Anemia; Anemia, Aplastic; Hepatitis; Hepatitis A; Hepatitis B vi

1964
CONGENITAL HYPOPLASIA OF THE EXOCRINE PANCREAS.
    Acta paediatrica, 1964, Volume: 53

    Topics: Agranulocytosis; Anemia; Biopsy; Child; Congenital Abnormalities; Cystic Fibrosis; Genetics, Medical

1964
THE USE OF CORTICOSTEROIDS IN NON-NEOPLASTIC BLOOD DISORDERS.
    Canadian Medical Association journal, 1964, Jun-27, Volume: 90

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anemia; Anemia, Aplastic; Anemia, Hemolytic; A

1964
DRUG-INDUCED BLOOD DYSCRASIAS. I. APLASTIC ANEMIA.
    JAMA, 1964, May-11, Volume: 188

    Topics: Acetazolamide; Anemia; Anemia, Aplastic; Anticonvulsants; Benzene; Chloramphenicol; Chlorothiazide;

1964
AUTO-IMMUNE ANTI-D SPECIFICITY IN INFANCY.
    American journal of diseases of children (1960), 1964, Volume: 108

    Topics: Anemia; Anemia, Hemolytic; Antibodies; Autoimmune Diseases; Blood Group Antigens; Blood Transfusion;

1964
[ON A NEW CASE OF CONGENITAL ERYTHROPOIETIC PORPHYRIA (GHUENTHER'S DISEASE)].
    La Pediatria, 1963, Dec-16, Volume: 71

    Topics: Anemia; Blood Chemical Analysis; Child; Humans; Liver Function Tests; Pathology; Porphyria, Erythrop

1963
PROLONGED SURVIVAL IN GOODPASTURE'S SYNDROME.
    Archives of internal medicine, 1964, Volume: 114

    Topics: Anemia; Anemia, Hypochromic; Anti-Glomerular Basement Membrane Disease; Glomerulonephritis; Hemoside

1964
ACUTE PROMYELOCYTIC LEUKAEMIA.
    The Medical journal of Australia, 1964, Jul-11, Volume: 2

    Topics: Anemia; Anemia, Myelophthisic; Blood Cell Count; Blood Sedimentation; Bone Marrow Examination; Hemor

1964
[VACUOLAR MYOPATHY IN DERMATOMYOSITIS (LUPUS ERYTHEMATOSUS)].
    Nederlands tijdschrift voor geneeskunde, 1964, Jul-04, Volume: 108

    Topics: Anemia; Anemia, Aplastic; Anti-Bacterial Agents; Dermatomyositis; Dexamethasone; Humans; Lupus Eryth

1964
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PRESENTING AS APLASTIC ANEMIA IN A CHILD. CASE REPORT WITH EVIDENCE OF DEFICIENT LEUKOCYTE ACETYLCHOLINESTERASE ACTIVITY.
    The American journal of medicine, 1964, Volume: 37

    Topics: Acetylcholinesterase; Alkaline Phosphatase; Anemia; Anemia, Aplastic; Biopsy; Blood Transfusion; Bon

1964
THE CONDITION OF ASTHMATIC PATIENTS AFTER DAILY LONG-TERM CORTICOSTEROID TREATMENT.
    Arizona medicine, 1964, Volume: 21

    Topics: Adrenal Cortex Hormones; Anemia; Anemia, Pernicious; Arizona; Asthma; Biopsy; Blood Chemical Analysi

1964
[PATHOGENESIS OF THE MEDULLARY INSUFFICIENCY IN AUTOIMMUNE ERYTHROBLASTIC APLASIA].
    Archivio "E. Maragliano" di patologia e clinica, 1964, Volume: 20

    Topics: Anemia; Anemia, Aplastic; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Autoantibodies; Bone Mar

1964
PHYTOHAEMAGGLUTININ.
    Lancet (London, England), 1964, Sep-19, Volume: 2, Issue:7360

    Topics: Anaphylaxis; Anemia; Anemia, Aplastic; Antigen-Antibody Reactions; Blood Transfusion; Bone Marrow Ex

1964
MASSIVE HEMORRHAGE--SCALPS OF NEWBORN INFANTS.
    American journal of diseases of children (1960), 1964, Volume: 108

    Topics: Anemia; Exchange Transfusion, Whole Blood; Factor VII Deficiency; Factor VIII; Hemophilia B; Hemorrh

1964
HAEMOLYTIC ANAEMIA ASSOCIATED WITH OVARIAN TERATOMA.
    British medical journal, 1964, Nov-21, Volume: 2, Issue:5420

    Topics: Anemia; Anemia, Hemolytic; Bilirubin; Blood Cell Count; Blood Chemical Analysis; Female; Hemoglobins

1964
[ANEMIA THERAPY IN CHILDHOOD].
    Monatsschrift fur Kinderheilkunde, 1964, Volume: 112

    Topics: Adolescent; Anemia; Blood Transfusion; Child; Cobalt; Drug Therapy; Humans; Infant; Infant, Newborn;

1964
[HEPARIN THERAPY OF ACQUIRED HEMOLYTIC ANEMIA].
    Acta haematologica, 1964, Volume: 32

    Topics: Anemia; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Anticoagulants; Complement System Proteins

1964
ANDROGENIC HORMONE THERAPY IN LYMPHATIC LEUKEMIA.
    JAMA, 1964, Dec-28, Volume: 190

    Topics: Anemia; Anemia, Aplastic; Erythropoiesis; Fluoxymesterone; Hemoglobins; Humans; Leukemia; Leukemia,

1964
RENAL HOMOTRANSPLANTATION IN 24 PATIENTS.
    British medical journal, 1965, Jan-02, Volume: 1, Issue:5426

    Topics: Anemia; Anemia, Macrocytic; Antineoplastic Agents; Azathioprine; Blood Group Incompatibility; Cadave

1965
PHYTOHAEMAGGLUTININ IN APLASTIC ANAEMIA.
    Lancet (London, England), 1964, Dec-19, Volume: 2, Issue:7373

    Topics: Anemia; Anemia, Aplastic; Blood Platelets; Blood Transfusion; Hemoglobins; Leukocyte Count; Neutroph

1964
[PURE ERYTHROBLASTOPENIA. APROPOS OF A CASE OF PRIMARY PURE ERYTHROBLASTOPENIA IN AN ADULT].
    La Presse medicale, 1964, Dec-19, Volume: 72

    Topics: Anemia; Anemia, Aplastic; Classification; Diagnosis, Differential; Geriatrics; Humans; Prednisone; R

1964
[STUDIES OF ERYTHROPOIESIS IN CHRONIC HYPOPLASTIC ANEMIA OF THE BLACKFAN-DIAMOND TYPE].
    Helvetica paediatrica acta, 1964, Volume: 19

    Topics: Anemia; Anemia, Aplastic; Bone Marrow Examination; Child; Erythrocyte Count; Erythropoiesis; Humans;

1964
THE SYNDROME OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.
    The American journal of medicine, 1964, Volume: 37

    Topics: Acetylcholinesterase; Alkaline Phosphatase; Anemia; Anemia, Hemolytic; Anticoagulants; Australia; Bl

1964
ANEMIA IN RHEUMATIC FEVER.
    Israel journal of medical sciences, 1965, Volume: 1

    Topics: Anemia; Anemia, Hemolytic; Aspirin; Blood Cell Count; Child; Drug Therapy; Hematocrit; Hemoglobinome

1965
CHRONIC ERYTHROCYTIC HYPOPLASIA FOLLOWING PERNICIOUS ANEMIA.
    Blood, 1965, Volume: 25

    Topics: Anemia; Anemia, Aplastic; Anemia, Pernicious; Blood Transfusion; Bone Marrow Examination; Clinical L

1965
CHRONIC ACTIVE ("LUPOID") HEPATITIS; A CLINICAL, SEROLOGICAL, AND PATHOLOGICAL STUDY OF 20 PATIENTS.
    Annals of internal medicine, 1965, Volume: 62

    Topics: Adolescent; Anemia; Arthritis; Autoantibodies; Blood Protein Disorders; Blood Protein Electrophoresi

1965
AUTO-IMMUNE HEMOLYTIC ANEMIA TREATED WITH D-PENICILLAMINE; REPORT OF A CASE.
    Annals of internal medicine, 1965, Volume: 62

    Topics: Anemia; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Autoantibodies; Blood Transfusion; Drug Th

1965
[CIRCULATORY BEHAVIOR IN LEUKOSES WITHOUT AND WITH THERAPY].
    Das Deutsche Gesundheitswesen, 1965, Jan-07, Volume: 20

    Topics: Anemia; Blood Circulation; Blood Transfusion; Drug Therapy; Geriatrics; Humans; Leukemia; Polycythem

1965
PHYTOHAEMAGGLUTININ IN TREATMENT OF APLASTIC ANAEMIA.
    Lancet (London, England), 1965, May-01, Volume: 1, Issue:7392

    Topics: Anemia; Anemia, Aplastic; Busulfan; Injections; Injections, Intravenous; Phenacetin; Phytohemaggluti

1965
PHYTOHAEMAGGLUTININ IN THE TREATMENT OF APLASTIC ANAEMIA.
    Lancet (London, England), 1965, May-29, Volume: 1, Issue:7396

    Topics: Anemia; Anemia, Aplastic; Drug Therapy; Phenylbutazone; Phytohemagglutinins; Plant Lectins; Predniso

1965
APLASTIC ANEMIA FOLLOWING EXPOSURE TO BENZENE HEXACHLORIDE (LINDANE).
    JAMA, 1965, Jul-12, Volume: 193

    Topics: Agranulocytosis; Anemia; Anemia, Aplastic; Child; Chlordan; DDT; Diagnosis; Drug Therapy; Ecchymosis

1965
FAMILIAL AUTO-IMMUNE HEMOLYTIC ANEMIA.
    Archives of internal medicine, 1965, Volume: 116

    Topics: Anemia; Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Coombs Test; Drug Therapy; gamma-Globuli

1965
[Drug-induced aplastic anemia complicated by diabetes mellitus during prednisone therapy].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1959, Sep-07, Volume: 14

    Topics: Anemia; Anemia, Aplastic; Diabetes Mellitus; Humans; Prednisone; Thiosemicarbazones; Tracheophyta

1959
[Erythropoiesis in Cooley's disease in relation to the administration of prednisone].
    Minerva pediatrica, 1960, Feb-25, Volume: 12

    Topics: Anemia; beta-Thalassemia; Child; Erythropoiesis; Hematopoiesis; Infant; Prednisone

1960
Effect of prednisone on B12 absorption in pernicious anaemia.
    Acta medica Scandinavica, 1960, Mar-30, Volume: 166

    Topics: Anemia; Anemia, Pernicious; Biochemical Phenomena; Humans; Prednisone; Tracheophyta; Vitamin B 12

1960
[Effects of prednisone on B12 absorption in pernicious anemia].
    Ugeskrift for laeger, 1959, Sep-17, Volume: 121

    Topics: Anemia; Anemia, Pernicious; Humans; Prednisone; Vitamin B 12

1959
Erythrocyte aplasia and hypogammaglobulinemia. Response to steroids in a young adult.
    Annals of internal medicine, 1961, Volume: 55

    Topics: Agammaglobulinemia; Anemia; Anemia, Aplastic; Humans; Prednisone; Red-Cell Aplasia, Pure; Steroids

1961
Severe hypoplastic anemia. Successful treatment with testosterone and prednisone.
    Northwest medicine, 1962, Volume: 61

    Topics: Anemia; Anemia, Aplastic; Humans; Prednisone; Testosterone; Tracheophyta

1962
True or absolute bone marrow failure. A ferrokinetic and therapeutic study.
    The American journal of the medical sciences, 1962, Volume: 244

    Topics: Anemia; Anemia, Aplastic; Bone Marrow; Humans; Iron; Prednisone

1962
Unprovoked periodontal hemorrhage, life-threatening anemia and idiopathic thrombocytopenia purpura: an unusual case report.
    Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry, 2003, Volume: 23, Issue:2

    Topics: Adult; Aminocaproic Acid; Anemia; Antifibrinolytic Agents; Diagnosis, Differential; Gingival Hemorrh

2003
Multiple complications in multiple myeloma.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:3

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Fractures, Spontaneous; Hip Fr

2005
Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine.
    Veterinary dermatology, 2005, Volume: 16, Issue:5

    Topics: Anemia; Animals; Carcinoma, Squamous Cell; Cyclosporine; Diagnosis, Differential; Dog Diseases; Dogs

2005
[Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
    Ai zheng = Aizheng = Chinese journal of cancer, 2005, Volume: 24, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols;

2005
Abnormal positron emission tomography (PET) scan secondary to the use of hematopoietic growth factors.
    Haematologica, 2005, Volume: 90, Issue:12 Suppl

    Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem

2005
Masked giant cell arteritis.
    Australian family physician, 2006, Volume: 35, Issue:11

    Topics: Aged; Anemia; Anti-Inflammatory Agents; Biopsy; Blood Sedimentation; Female; Giant Cell Arteritis; H

2006
[Fatigue, loss of appetite and anuria due to retroperitoneal fibrosis].
    Nederlands tijdschrift voor geneeskunde, 2007, Jan-20, Volume: 151, Issue:3

    Topics: Aged; Anemia; Anti-Inflammatory Agents; Anuria; Diagnosis, Differential; Fatigue; Feeding and Eating

2007
Chronic anemia and thrombocytosis as the initial presentation of Still's disease in an elderly patient.
    Gerontology, 2007, Volume: 53, Issue:5

    Topics: Aged; Anemia; Antirheumatic Agents; Chronic Disease; Female; Glucocorticoids; Humans; Methotrexate;

2007
Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone.
    The Journal of dermatological treatment, 2007, Volume: 18, Issue:4

    Topics: Anemia; Drug Therapy, Combination; Erythrocyte Count; Female; Humans; Immunosuppressive Agents; Midd

2007
Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2007, Volume: 13, Issue:11

    Topics: Anemia; Antibodies; Antiviral Agents; Epoetin Alfa; Erythropoietin; Graft Rejection; Hematinics; Hep

2007
Comment on: 'Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome'.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7

    Topics: Administration, Oral; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Ble

2008
Familial leukemia: uncommon type of chronic lymphocytic leukemia in two sisters.
    Haematologica, 1982, Volume: 67, Issue:3

    Topics: Agammaglobulinemia; Anemia; Chlorambucil; Female; Humans; Leukemia, Lymphoid; Middle Aged; Prednison

1982
[Angioimmunoblastic lymphadenopathy. Case report].
    Minerva medica, 1982, Dec-22, Volume: 73, Issue:49-50

    Topics: Anemia; Body Weight; Female; Fever; Hepatomegaly; Humans; Immunoblastic Lymphadenopathy; Immunosuppr

1982
Long-term assessment of chlorambucil in children with nephrotic syndrome who fail to respond adequately to corticosteroids.
    Contributions to nephrology, 1981, Volume: 27

    Topics: Adolescent; Anemia; Bacterial Infections; Child; Child, Preschool; Chlorambucil; Drug Resistance; Fe

1981
Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University.
    Japanese journal of cancer research : Gann, 1994, Volume: 85, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antineoplastic Agents; Ant

1994
Severe anemia as the presenting manifestation of giant cell arteritis.
    Arthritis and rheumatism, 1995, Volume: 38, Issue:3

    Topics: Aged; Anemia; Biopsy; Female; Giant Cell Arteritis; Humans; Male; Prednisone

1995
Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.
    Leukemia & lymphoma, 1994, Volume: 14, Issue:1-2

    Topics: 2-Chloroadenosine; Anemia; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD4-Positive

1994
Case report: hypercalcemia with inappropriate 1,25-dihydroxyvitamin D in Wegener's granulomatosis.
    The American journal of the medical sciences, 1994, Volume: 308, Issue:2

    Topics: Aged; Anemia; Calcitriol; Calcium; Creatinine; Cyclophosphamide; Female; Granulomatosis with Polyang

1994
Hypereosinophilic syndrome presenting with diarrhoea and anaemia in a patient with systemic lupus erythematosus.
    The Netherlands journal of medicine, 1998, Volume: 52, Issue:2

    Topics: Adult; Anemia; Diarrhea; Female; Follow-Up Studies; Glucocorticoids; Humans; Hypereosinophilic Syndr

1998
[A case of post-partum remission of acquired dyserythropoiesis, a rare cause of anemia in disseminated lupus erythematosus].
    La Revue de medecine interne, 1998, Volume: 19, Issue:8

    Topics: Adult; Anemia; Anti-Inflammatory Agents; Cells, Cultured; Erythroid Precursor Cells; Erythropoiesis;

1998
A case of mu heavy-chain disease associated with hyperglobulinemia, anemia, and a positive Coombs test.
    Annals of hematology, 1998, Volume: 77, Issue:5

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Grouping and Cro

1998
Steroid hormone-responsive secondary factor X deficiency.
    Thrombosis and haemostasis, 1998, Volume: 80, Issue:6

    Topics: Aged; Anemia; Diabetes Mellitus; Factor X Deficiency; Glucocorticoids; Hemorrhage; Humans; Male; Par

1998
Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid.
    Journal of the American Academy of Dermatology, 1999, Volume: 40, Issue:5 Pt 1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Dermatologic Agents; Exudates and Transudates

1999
[Acute leukemia in Jehovah's Witnesses].
    Sangre, 1999, Volume: 44, Issue:5

    Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Transfusion; Chri

1999
A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Haematologica, 2000, Volume: 85, Issue:3

    Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclopho

2000
Corticosteroid-responsive thrombocytopenia in two beef cows.
    Journal of the American Veterinary Medical Association, 2000, Sep-01, Volume: 217, Issue:5

    Topics: Anemia; Animals; Cattle; Cattle Diseases; Dexamethasone; Epistaxis; Female; Glucocorticoids; Hematom

2000
Light and electron microscopic features of eperythrozoon-like parasites in a North American opossum (Didelphis virginiana).
    Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians, 2000, Volume: 31, Issue:2

    Topics: Anemia; Animals; Anti-Bacterial Agents; Antinematodal Agents; Blood Chemical Analysis; Doxycycline;

2000
Lupus nephritis in children: prognostic significance of clinicopathological findings.
    Nephron, 2001, Volume: 87, Issue:2

    Topics: Adolescent; Anemia; Blood Pressure; Child; Child, Preschool; Creatinine; Cyclophosphamide; Female; H

2001
Experiences with leflunomide in solid organ transplantation.
    Transplantation, 2002, Feb-15, Volume: 73, Issue:3

    Topics: Anemia; Calcineurin Inhibitors; Creatinine; Humans; Immunosuppressive Agents; Isoxazoles; Kidney Tra

2002
Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy.
    Onkologie, 2002, Volume: 25, Issue:1

    Topics: Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamid

2002
Failure of G-CSF therapy in neutropenia associated with Sjögren's syndrome.
    Rheumatology (Oxford, England), 2002, Volume: 41, Issue:4

    Topics: Amikacin; Anemia; Anti-Bacterial Agents; Female; Filgrastim; Granulocyte Colony-Stimulating Factor;

2002
Decreases in mean hemoglobin and serum albumin values in erythema nodosum leprosum and lepromatous leprosy.
    International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 2001, Volume: 69, Issue:4

    Topics: Anemia; Dapsone; Erythema Nodosum; Hemoglobins; Humans; Leprostatic Agents; Leprosy, Lepromatous; Pr

2001
Anemia associated with feline leukemia virus infection.
    Journal of the American Veterinary Medical Association, 1979, Dec-01, Volume: 175, Issue:11

    Topics: Androgens; Anemia; Animals; Blood Transfusion; Bone Marrow Examination; Cat Diseases; Cats; Leukemia

1979
Immunoblastic lymphadenopathy with purpura and cryoglobulinemia.
    Archives of dermatology, 1977, Volume: 113, Issue:5

    Topics: Allopurinol; Anemia; B-Lymphocytes; Cryoglobulins; Female; Humans; Leukopenia; Lymphatic Diseases; M

1977
Multiple myeloma: uncommon or uncommonly diagnosed?
    Postgraduate medicine, 1977, Volume: 61, Issue:5

    Topics: Adult; Anemia; Blood Sedimentation; Bone Diseases; Female; Humans; Male; Melphalan; Middle Aged; Mul

1977
Acute lymphoblastic leukemia terminating as histiocytic medullary reticulosis.
    JAMA, 1975, Feb-24, Volume: 231, Issue:8

    Topics: Acute Disease; Adult; Anemia; Autopsy; Bone Marrow; Erythrocytes; Hepatomegaly; Humans; Leukemia, Ly

1975
The evolution into and the treatment of late stage polycythemia vera.
    Seminars in hematology, 1976, Volume: 13, Issue:1

    Topics: Anemia; Female; Humans; Iron; Male; Phosphorus Radioisotopes; Polycythemia Vera; Prednisone; Primary

1976
Arteritis of the aged (giant cell arteritis) and fever of unexplained origin.
    The American journal of medicine, 1976, Volume: 60, Issue:3

    Topics: Aged; Anemia; Blood Sedimentation; Diagnosis, Differential; Female; Fever of Unknown Origin; Giant C

1976
Selective metaphasic arrest of erythroblasts by vincristine in patients receiving high doses of recombinant human erythropoietin for myelosuppressive anemia.
    Leukemia, 1992, Volume: 6 Suppl 4

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Erythroblasts; Erythropoietin; Hodgkin Disea

1992
A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
    Journal of biological response modifiers, 1989, Volume: 8, Issue:3

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality

1989
[Erythroblastopenia associated with chronic myelomonocytic leukemia].
    Sangre, 1989, Volume: 34, Issue:4

    Topics: Aged; Anemia; Bone Marrow; Erythroblasts; Humans; Leukemia, Myelomonocytic, Chronic; Male; Mercaptop

1989
[Crohn's disease in children and adolescents].
    Archives francaises de pediatrie, 1985, Volume: 42, Issue:8

    Topics: Adolescent; Anemia; Child; Crohn Disease; Drug Therapy, Combination; Female; Growth Disorders; Human

1985
Cyclosporine experience in renal transplantation in children.
    The Mount Sinai journal of medicine, New York, 1987, Volume: 54, Issue:6

    Topics: Adolescent; Anemia; Azathioprine; Child; Creatinine; Cyclosporins; Female; Gingival Hyperplasia; Gra

1987
The anemia of sarcoidosis.
    Sarcoidosis, 1988, Volume: 5, Issue:1

    Topics: Adult; Anemia; Bone Marrow; Female; Granuloma; Humans; Iron; Leukopenia; Lung Diseases; Male; Predni

1988
Sarcoidosis. Usual and unusual manifestations.
    Chest, 1988, Volume: 94, Issue:1

    Topics: Anemia; Female; Humans; Hypercalcemia; Liver Diseases; Lung Diseases; Methotrexate; Middle Aged; Pre

1988
Diamond-Blackfan syndrome in adult patients.
    The American journal of medicine, 1985, Volume: 78, Issue:3

    Topics: Adult; Aged; Anemia; Blood Transfusion; Bone Marrow; Erythrocyte Count; Erythrocyte Transfusion; Fem

1985
[Whipple's disease. Case report (author's transl)].
    Acta gastro-enterologica Belgica, 1974, Volume: 37, Issue:4

    Topics: Anemia; Biopsy; Cholecystectomy; Cholelithiasis; Diarrhea; Edema; Humans; Intestinal Mucosa; Jejunum

1974
Case for diagnosis: leukocytoclastic vasculitis.
    Proceedings of the Royal Society of Medicine, 1973, Volume: 66, Issue:5

    Topics: Anemia; Arteritis; Blood Sedimentation; Body Weight; Dapsone; Diagnosis, Differential; Humans; Leuko

1973
[Studies on blood mast cell leukemias].
    Blut, 1968, Volume: 18, Issue:1

    Topics: Alkaline Phosphatase; Anemia; Bone Marrow Examination; Female; Hematoma, Subdural; Hemorrhagic Disor

1968
A heart transplantation. 8. Immunological and haematological aspects.
    The Medical journal of Australia, 1969, Mar-29, Volume: 1, Issue:13

    Topics: ABO Blood-Group System; Anaphylaxis; Anemia; Antibodies; Antilymphocyte Serum; Australia; Azathiopri

1969
[Lymphoid hepatosplenomegaly].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1968, Mar-20, Volume: 44, Issue:14

    Topics: Adrenal Cortex Hormones; Aged; Anemia; Blood Transfusion; Hepatomegaly; Humans; Leukemia, Lymphoid;

1968
Combination chemotherapy in accelerated phase of chronic granulocytic leukemia.
    Archives of internal medicine, 1969, Volume: 123, Issue:2

    Topics: Adolescent; Adult; Aged; Anemia; Blood Platelets; Blood Transfusion; Blood Urea Nitrogen; Bone Marro

1969
Alternate-day corticosteroid therapy in juvenile chronic polyarthritis.
    The Journal of rheumatology, 1974, Volume: 1, Issue:2

    Topics: Adolescent; Anemia; Arthritis, Juvenile; Body Height; Child; Child, Preschool; Chronic Disease; Drug

1974
Response to therapy confirms diagnosis.
    Geriatrics, 1973, Volume: 28, Issue:7

    Topics: Aged; Anemia; Blood Sedimentation; Diuretics; Edema; Female; Hemoglobinometry; Humans; Leukocytosis;

1973
The use of different drugs and combinations in the treatment of Hodgkin's disease.
    Series haematologica (1968), 1973, Volume: 6, Issue:2

    Topics: Administration, Oral; Anemia; Drug Evaluation; Drug Therapy, Combination; Hodgkin Disease; Humans; I

1973
Corticosteroid therapy in Felty's syndrome and its effect on hypersplenic rats.
    British journal of haematology, 1974, Volume: 26, Issue:2

    Topics: Aged; Anemia; Animals; Body Weight; Chromium Radioisotopes; Disease Models, Animal; Felty Syndrome;

1974
Azathioprine for pemphigus and pemphigoid--a 4 year follow-up.
    The British journal of dermatology, 1974, Volume: 91, Issue:1

    Topics: Adult; Aged; Anemia; Azathioprine; Bone Neoplasms; Drug Evaluation; Drug Hypersensitivity; Female; F

1974
Erythropoietin activity in anephric or renal allotransplanted man.
    Annals of surgery, 1969, Volume: 170, Issue:4

    Topics: Adult; Androgens; Anemia; Animals; Azathioprine; Blood Urea Nitrogen; Bone Marrow; Erythropoietin; F

1969
Renal homotransplantation in children.
    The Journal of pediatrics, 1970, Volume: 76, Issue:3

    Topics: Adaptation, Psychological; Adolescent; Anemia; Azathioprine; Cadaver; Child; Child, Preschool; Cyclo

1970
Combination chemotherapy of Hodgkin's disease in private practice.
    JAMA, 1972, Jul-17, Volume: 221, Issue:3

    Topics: Adolescent; Adult; Aged; Anemia; Biopsy; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Mid

1972
[Hematologic therapy of malignant lymphoma].
    Wiener klinische Wochenschrift, 1971, Jul-09, Volume: 83, Issue:27

    Topics: Anemia; Blood Platelets; Blood Transfusion; Erythrocytes; Female; Hodgkin Disease; Humans; Lymphoma;

1971
Myelofibrosis with unusual neurologic abnormalities.
    The American journal of medicine, 1971, Volume: 51, Issue:6

    Topics: Aged; Ampicillin; Anemia; Blood Platelet Disorders; Bone and Bones; Brain; Dyspnea; Female; Heart; H

1971
Myelofibrosis and myeloid leukaemia.
    Acta paediatrica Scandinavica, 1967, Volume: 56, Issue:4

    Topics: Anemia; Biopsy; Blood Transfusion; Child, Preschool; Erythrocyte Count; Hepatomegaly; Humans; Leukem

1967
Treatment of AGL.
    Archives of internal medicine, 1969, Volume: 123, Issue:2

    Topics: Adult; Afibrinogenemia; Aged; Anemia; Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Humans

1969
Paroxysmal nocturnal hemoglobinuria terminating in acute granulocytic leukemia.
    Blood, 1969, Volume: 33, Issue:2

    Topics: Androgens; Anemia; Blood Cell Count; Blood Transfusion; Bone Marrow Examination; Cyclophosphamide; H

1969
Cytarabine.
    The Medical letter on drugs and therapeutics, 1971, Jan-08, Volume: 13, Issue:1

    Topics: Acute Disease; Amino Sugars; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents; Blood Cell

1971
Agnogenic myeloid metaplasia; its current managment.
    Minnesota medicine, 1970, Volume: 53, Issue:3

    Topics: Anemia; Female; Fluoxymesterone; Humans; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Splen

1970
Shortened red cell survival in chronic posthaemorrhagic anaemia: effect of iron and prednisone.
    British journal of haematology, 1970, Volume: 18, Issue:6

    Topics: Adolescent; Adult; Aged; Anemia; Blood Volume; Chromium Isotopes; Erythrocyte Aging; Erythropoiesis;

1970
[Effect of therapy on iron metabolism in patients with progressive chronic polyarthritis].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1970, Sep-15, Volume: 25, Issue:18

    Topics: Anemia; Anemia, Hypochromic; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Blood Sedimentation; B

1970
Osteopetrosis from the ophthalmological point of view. A report of two cases.
    Acta ophthalmologica, 1970, Volume: 48, Issue:4

    Topics: Anemia; Female; Genes, Recessive; Humans; Infant; Male; Optic Atrophy; Optic Nerve; Osteopetrosis; P

1970
Empyema in rheumatoid pleuropulmonary disease.
    Annals of internal medicine, 1971, Volume: 74, Issue:5

    Topics: Adult; Aged; Anemia; Arthritis, Rheumatoid; Bronchial Fistula; Empyema; Female; Glucose; Humans; Lun

1971
Mu-chain disease.
    Annals of internal medicine, 1971, Volume: 75, Issue:3

    Topics: Adult; Agammaglobulinemia; Anemia; Bence Jones Protein; Chlorambucil; Female; Fractures, Bone; Heavy

1971
Steroid induced gastric regeneration and functional recovery.
    Gastrointestinal endoscopy, 1967, Volume: 14, Issue:1

    Topics: Achlorhydria; Aged; Anemia; Female; Gastric Mucosa; Hemoglobins; Humans; Prednisone; Regeneration; S

1967
[Fiessinger-Leroy-Reiter's disease in a woman, with cardiac and anemic complications and fatal development].
    Bulletin de la Societe francaise de dermatologie et de syphiligraphie, 1968, Volume: 75, Issue:1

    Topics: Adult; Anemia; Arthritis, Reactive; Female; Humans; Prednisone; Sex Factors; Tachycardia

1968
Effect of artificially induced abacterial erysipelas and of chronic aseptic abscess on human and experimental neoplasms.
    Polish medical journal, 1968, Volume: 7, Issue:5

    Topics: Abscess; Adult; Aged; Amylases; Anemia; Animals; Breast Neoplasms; Child; Erysipelas; Eye Neoplasms;

1968
Abnormal (marker) chromosomes in two patients with acute myelofibrosis.
    Archives of internal medicine, 1969, Volume: 123, Issue:2

    Topics: Aged; Anemia; Anti-Bacterial Agents; Blood Cell Count; Blood Cells; Blood Chemical Analysis; Blood T

1969
[Retroperitoneal fibrosis. A case with unusual symptomatology].
    Nordisk medicin, 1969, May-08, Volume: 81, Issue:19

    Topics: Aged; Anemia; Blood Sedimentation; Diagnosis, Differential; Female; Fever; Humans; Polymyalgia Rheum

1969
[Chlorambucil in the treatment of idiopathic nephrotic syndrome without glomrular lesions in childhood. Apropos of 30 cases].
    Annales de pediatrie, 1969, Jan-02, Volume: 16, Issue:1

    Topics: Adolescent; Anemia; Biopsy; Child; Child, Preschool; Chlorambucil; Female; Glucocorticoids; Humans;

1969
Alkeran and multiple myeloma.
    The Medical letter on drugs and therapeutics, 1966, Apr-22, Volume: 8, Issue:8

    Topics: Anemia; Cyclophosphamide; Humans; Leukopenia; Melphalan; Multiple Myeloma; Prednisone; Urethane

1966
[Anemia in the course of lymphatic leukemia].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1966, Aug-01, Volume: 21, Issue:31

    Topics: Anemia; Humans; Leukemia, Lymphoid; Male; Middle Aged; Prednisone; Thrombocytopenia

1966
[On the clinical aspects of essential lung hemosiderosis].
    Zeitschrift fur arztliche Fortbildung, 1966, Jul-01, Volume: 60, Issue:13

    Topics: Anemia; Female; Hemosiderosis; Humans; Lung Diseases; Middle Aged; Prednisone; Pulmonary Heart Disea

1966